Early View

Original research article

Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study

Emilie J. Lambourg, Peter J. Gallacher, Robert W. Hunter, Moneeza Siddiqui, Eve Miller-Hodges, James Chalmers, Dan Pugh, Neeraj Dhaun, Samira Bell

Please cite this article as: Lambourg EJ, Gallacher PJ, Hunter RW, et al. Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study. *Eur Respir J* 2022; in press (https://doi.org/10.1183/13993003.03168-2021).

This manuscript has recently been accepted for publication in the *European Respiratory Journal*. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study

Emilie J. Lambourg*, PharmD,1 Peter J. Gallacher*, MBChB MPH,2 Robert W. Hunter, MBChB PhD,2,3 Moneeza Siddiqui, PhD,1 Eve Miller-Hodges, MBChB PhD,2,3 James Chalmers, MBChB PhD,4 Dan Pugh, MBChB,3 Neeraj Dhaun†, MBChB PhD,2,3 Samira Bell†, MBChB MD1

1 Division of Population Health and Genomics, University of Dundee, Dundee, UK
2 BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
3 Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK
4 Department of Molecular and Clinical Medicine, University of Dundee, Dundee, UK

*These authors contributed equally
†These authors contributed equally

Corresponding author:
Dr. Neeraj Dhaun (Bean)
BHF/University Centre for Cardiovascular Science
University of Edinburgh
Edinburgh EH16 4SA
United Kingdom
E-mail: bean.dhaun@ed.ac.uk

Abstract: 249

Word count: 3,253

Tables & Figures: 2 + 2

References: 35
Abstract

**Background:** Data describing cardiovascular outcomes in patients with COVID-19 and chronic kidney disease (CKD) are lacking. We compared cardiovascular outcomes of patients with and without COVID-19, stratified by CKD status.

**Methods:** This retrospective, multi-regional data-linkage study utilised individual patient-level data from two Scottish cohorts. All patients tested for SARS-CoV-2 in Cohort 1 between 01/02/2020 and 31/03/2021, and in Cohort 2 between 28/02/2020 and 08/02/2021, were included.

**Results:** Overall, 86,964 patients were tested for SARS-CoV-2. There were 36,904 patients (61±21 years, 58.1% women, 15.9% CKD, 10.1% COVID-19 positive) in Cohort 1 and 50,060 patients (63±20 years, 62.0% women, 16.4% CKD, 9.1% COVID-19 positive) in Cohort 2. In CKD patients, COVID-19 increased the risk of cardiovascular death by more than two-fold within 30 days (cause-specific hazard ratio [csHR] meta-estimate 2.34, 95% confidence interval [CI] 1.83-2.99), and by 57% at the end of follow-up (csHR meta-estimate 1.57, 95% CI 1.31-1.89). Similarly, the risk of all-cause death in COVID-19 positive versus negative CKD patients was greatest within 30 days (HR 4.53, 95% CI 3.97-5.16). Compared to patients without CKD, those with CKD had a higher risk of testing positive (11.5% versus 9.3%). Following a positive test, CKD patients had higher rates of cardiovascular death (11.1% versus 2.7%), cardiovascular complications, and cardiovascular hospitalisations (7.1% versus 3.3%) than those without CKD.

**Conclusions:** COVID-19 increases the risk of cardiovascular and all-cause death in CKD patients, especially in the short-term. CKD patients with COVID-19 are also at a disproportionate risk of cardiovascular complications than those without CKD.
Introduction

Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),\(^1\) has had an unprecedented public health, societal and economic impact. Disease severity in patients with COVID-19 can vary markedly, from no symptoms or a mild respiratory illness, to life-threatening pulmonary and extra-pulmonary complications and death.\(^2\) Several factors have been identified that increase disease severity. These include older age, male sex, social deprivation, obesity, and comorbidities such as cardiovascular disease and chronic kidney disease (CKD).\(^3\)\(^-\)\(^8\) The risk of critical illness and death following COVID-19 increases as kidney function declines, such that patients with the most advanced CKD have the poorest outcomes.\(^4\)\(^,\)\(^9\)\(^-\)\(^11\)

The commonest complication of CKD is cardiovascular disease.\(^12\) As estimated glomerular filtration rate (eGFR) declines, the risk of cardiovascular disease and major adverse cardiovascular events increases.\(^13\) Whilst pre-existing cardiovascular disease is a risk factor for COVID-19 severity, several studies have also suggested that myocardial injury and cardiovascular complications are common following COVID-19 and associated with worse outcomes for these patients.\(^14\)\(^-\)\(^16\)

However, data describing the nature and frequency of cardiovascular outcomes in patients with CKD and COVID-19 are lacking. Specifically, it is unclear how COVID-19 modifies the existing cardiovascular risk in patients with CKD in the short- and medium-term. In this unique multi-regional data-linkage study, we evaluated the clinical characteristics and cardiovascular outcomes of patients with and without COVID-19, stratified by the presence or absence of CKD.
Methods

Patient population and study design

We conducted a retrospective, multi-regional study utilising linked individual patient-level data from two cohorts in Scotland, United Kingdom. All SARS-CoV-2 polymerase chain reaction tests performed during the relevant time periods described for each cohort were included, regardless of whether they were from a hospital or community setting, and irrespective of their indication (e.g. clinical, screening, or research). Each patient’s index COVID-19 status was defined as follows: 1) COVID-19 positive – where a patient first recorded a positive SARS-CoV-2 test result, they were included as an index positive episode occurring on that date. In this sub-population, prior or subsequent negative SARS-CoV-2 test results within the study period were excluded, as were subsequent positive SARS-CoV-2 test results. 2) COVID-19 negative – where a patient first recorded a negative SARS-CoV-2 test result, but in the absence of any prior or subsequent positive test result, they were included as an index negative episode occurring on that date. In this sub-population, subsequent negative SARS-CoV-2 test results were also excluded. The date of each index positive or negative episode was assigned as the index date.

Study cohorts

Cohort 1

All patients who had a SARS-CoV-2 test in the NHS Lothian Health Board between 02/01/2020 and 03/31/2021 were identified. Positive and negative COVID-19 episodes were linked with regional electronic patient and biochemistry records and national hospitalisation, dispensed community prescription and death records within the DataLoch Repository and Safe Haven (University of Edinburgh/NHS Lothian, Scotland) (Appendix).

Cohort 2

All patients who had had a measure of serum creatinine in the NHS Fife or Tayside Health Boards since 04/01/2009, and subsequently had a SARS-CoV-2 test between 02/28/2020, and 02/08/2021, were identified. Positive and negative COVID-19 episodes were defined as for Cohort 1 before being linked with national hospitalisation, dispensed community prescription, and death
records within the Health Informatics Centre Safe Haven (University of Dundee/NHS Fife and Tayside, Scotland) (Appendix).\textsuperscript{17}

\textbf{Determination of patient demographics, CKD status, comorbidities and causes of death}

Patient age, sex and socio-economic status were determined from linked hospitalisation records. Socio-economic status was defined according to the Scottish Index of Multiple Deprivation – a validated measure of social deprivation determined by factors related to residential address (zip code) (Appendix).\textsuperscript{18} CKD status was determined at the time of index SARS-CoV-2 test utilising the same, previously validated criteria for both study cohorts.\textsuperscript{19} eGFRs were calculated for all serum creatinine results using the Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration equation.\textsuperscript{20} CKD was defined when a patient’s most recent eGFR was <60 ml/min/1.73m\textsuperscript{2} and at least one value obtained >90 days prior was also <60 ml/min/1.73m\textsuperscript{2}. Using the eGFR value closest to the index date for each patient, CKD stage was classified according to ‘Kidney Disease: Improving Global Outcomes’ guidelines.\textsuperscript{21} Patients with kidney failure requiring kidney replacement therapy (i.e. haemodialysis, peritoneal dialysis or kidney transplantation) were identified from record linkage with regional or national renal registries (Cohort 1 – VitalData; Cohort 2 – Scottish Renal Registry). Those patients with only a single measure of eGFR <60 ml/min/1.73m\textsuperscript{2} prior to their index test were excluded (Supplementary Figure 1).

Patient comorbidities (i.e. angina, atrial fibrillation, cancer, chronic liver disease, chronic lower respiratory disease, heart failure, myocardial infarction, and stroke) were defined from International Classification of Diseases (ICD) codes associated with hospitalisations during a 5-year ‘lookback’ period prior to the index SARS-CoV-2 test (Appendix). Diabetes status was obtained via record linkage with a national diabetes registry (Scottish Care Information – Diabetes Collaboration).\textsuperscript{22} History of prescribed medications was determined from the community prescribing records of individual patients during the 6 months preceding their index SARS-CoV-2 test. Causes of death were determined following the identification of relevant ICD codes in linked National Records of Scotland death records (Appendix).
Study follow-up and outcomes

Patients were followed-up from the index date until either their date of death or April 30, 2021 (Cohort 1) or May 20, 2021 (Cohort 2), whichever came first. For both study cohorts, information relating to primary and secondary causes of death was obtained via record linkage with the National Records of Scotland death registry (Appendix). Primary outcomes included cardiovascular, COVID-19-related, and all-cause death. Secondary outcomes included subsequent fatal and non-fatal myocardial infarction, heart failure or stroke, hospitalisation for cardiovascular diagnoses, hospitalisation for any reason and length of hospital stay. For each cohort, outcomes were reported at 30 days, 90 days and to the end of follow-up.

Statistical analysis

Summary statistics

Baseline clinical characteristics and crude outcomes for all index SARS-CoV-2 tests included in each cohort were summarised according to CKD and COVID-19 status. Continuous variables were presented as medians and interquartile ranges and categorical variables were presented as percentages. Where appropriate, groupwise comparisons were performed using Chi-square tests.

Covariate-balanced propensity scoring and regression modelling

With the aim of obtaining unconfounded estimates, we utilised a ‘doubly-robust’ estimator with bootstrapped standard errors and 95% confidence intervals in our evaluation of the primary outcomes (Appendix). This approach combines a multivariable outcome regression model with weighting by the covariate-balanced propensity score (CBPS). For the primary analysis, Cox regression was used to explore the association between COVID-19 status (the primary exposure) and cardiovascular and all-cause death (the primary outcomes). For the secondary analysis, Cox regression was used to explore the association between CKD status (the primary exposure) and cardiovascular, COVID-19 and all-cause death (the primary outcomes). Confounders were specified a priori and included age, sex, socio-economic status, comorbidities (i.e. angina, myocardial infarction, heart failure, stroke, diabetes, cancer, chronic respiratory disease, chronic liver disease) and selected current medication (ACE-inhibitors/ARBs, immunosuppressant therapy)
based on their potential relevance to COVID-19 outcomes.\textsuperscript{24, 25} For each primary outcome, hazard ratios derived from CBPS-weighted, adjusted multivariable models in individual cohorts were pooled using a fixed-effects model to obtain an overall meta-estimate (Appendix). Finally, a sensitivity analysis was also performed to evaluate the effect of restricting the cohorts to those patients not hospitalised either in the week before or in the two weeks following their index COVID-19 test. All data were analysed using the R statistical programming language (Version 3.6.2, Vienna, Austria).

**Ethical approval**

The study was performed with the approvals of local Research Ethics Committees and delegated Caldicott Guardians for the NHS Fife, Lothian, and Tayside Health Boards, in accordance with the Declaration of Helsinki (Appendix). Data provision and linkage were carried out by the DataLoch (University of Edinburgh/NHS Lothian, https://www.dataloch.org/) and University of Dundee Health Informatics Centre (HIC, https://www.dundee.ac.uk/hic) within ISO27001 and Scottish Government accredited secure Safe Havens for Cohorts 1 and 2, respectively. Patient consent was not sought as the study utilised fully-anonymised data. Our analysis code is publicly available [here](https://www.dataloch.org/).
Results

Study cohorts

In total, 86,964 of 102,894 (84.5%) patients tested for SARS-CoV-2 were included in the study (Supplementary Figure 1). There were 36,904 patients (61±21 years; 58.1% women) in Cohort 1 and 50,060 patients (63±20 years; 62.0% women) in Cohort 2. Overall, the distribution of patient demographics and clinical characteristics between each cohort was similar. CKD was present in 15.9% (5,853/36,904) of patients in Cohort 1 and 16.4% (8,201/50,060) of patients in Cohort 2 (Supplementary Table 1), whilst a positive SARS-CoV-2 test was recorded in 10.1% (3,731/36,904) and 9.1% (4,556/50,060) of patients in Cohorts 1 and 2, respectively (Supplementary Table 2). In both cohorts, CKD was commoner in patients with COVID-19 than in those without (Cohort 1: 19.7% versus 15.4%; Cohort 2: 19.0% versus 16.1%).

Baseline characteristics of patients with CKD according to COVID-19 status

In patients with CKD, those with COVID-19 were older and more socially deprived than those without COVID-19 (Table 1). Although SARS-CoV-2 testing was performed more frequently in women than in men with CKD (Cohort 1: 53.8% versus 46.2%; Cohort 2: 59.5% versus 40.5%) (Supplementary Table 3), the proportion of women testing positive and negative was similar (Cohort 1: 52.3% versus 54.0%; Cohort 2: 58.0% versus 59.7%) (Table 1). Patients with CKD who tested positive had higher rates of cardiovascular comorbidity but similar eGFR compared to patients who tested negative. Despite this, across both cohorts, patients with CKD who tested positive were less likely to be prescribed an ACE-inhibitor or ARB at the time of their index SARS-CoV-2 test than those who tested negative (Cohort 1: 35.8% versus 41.5%; Cohort 2: 25.2% versus 36.7%) (Table 1). The baseline characteristics of patients without CKD summarised according to COVID-19 status (Table 1), and of patients with and without COVID-19 summarised according to CKD status (Supplementary Table 4), are described in the Supplementary Results.

Outcomes of patients with CKD according to COVID-19 status

In patients with CKD, the crude rate of cardiovascular death at 30 days in those with COVID-19 was double that of patients without COVID-19 (Cohort 1: 7.8% versus 3.4%; Cohort 2: 7.2% versus
3.5%) (Table 2; Figure 1a; Supplementary Table 5). After balancing differences in covariates between positive and negative patients (Supplementary Figure 2) – and following adjustment for confounders – this increase in short-term cardiovascular risk persisted and was more than two-fold higher in positive than in negative patients at 30 days (cause-specific hazard ratio [csHR] meta-estimate 2.34, 95% confidence interval [CI] 1.83 to 2.99) (Figure 2a). By the end of study follow-up, the difference in cardiovascular risk between positive and negative patients with CKD had narrowed (csHR meta-estimate 1.57, 95% CI 1.31 to 1.89) (Figures 1a & 2a).

In patients with CKD, the risk of all-cause death at 30 days in those with COVID-19 was substantially higher than in those without COVID-19 (Cohort 1: 35.4% versus 8.6%; Cohort 2: 34.9% versus 8.8%) (Table 2; Figure 1b; Supplementary Table 5). In the fully adjusted models, the risk of all-cause death in patients with CKD and COVID-19 was increased more than four-fold at 30 days (HR meta-estimate 4.53, 95% CI 3.97 to 5.16), and by more than two-fold overall (HR meta-estimate 2.41, 95% CI 2.17 to 2.64) compared to those with CKD testing negative. In contrast, cardiovascular complications and subsequent hospitalisations were lower in positive than in negative patients with CKD at 30 days, 90 days and to the end of study follow-up (Table 2).

In a sensitivity analysis restricted to patients with CKD not hospitalised either in the week before or in the two weeks following their index COVID-19 test, overall rates of cardiovascular and all-cause death were lower than those reported in the primary analysis (Supplementary Table 6). However, COVID-19 was associated with a significantly increased risk of cardiovascular and all-cause death at all time points, especially in the short-term – a pattern which was comparable to the primary analysis (Supplementary Table 7).

Outcomes of patients with COVID-19 according to CKD status and eGFR

In patients with COVID-19, those with CKD had a higher risk of cardiovascular death than those without CKD (csHR meta-estimate 1.64, 95% CI 1.29 to 2.10) (Supplementary Table 8; Supplementary Figures 3 & 4). Similarly, CKD was associated with a significantly increased risk of all-cause death in patients testing positive (csHR meta-estimate 1.25, 95% CI 1.12 to 1.41) (Supplementary Table 8; Supplementary Figures 3 & 4). When eGFR was analysed as a
continuous variable, the risk of both cardiovascular and all-cause death increased as kidney function declined (Supplementary Figure 5).

In patients with COVID-19, CKD was associated with an increased risk of COVID-19-related death (csHR meta-estimate 1.27, 95% CI 1.12 to 1.43) (Supplementary Table 8 & Supplementary Figure 6). Again, the risk of COVID-19-related death increased significantly as eGFR declined, even after adjustment for confounders (Supplementary Figure 7). Rates of cardiovascular complications and subsequent hospitalisations were also higher in COVID-19 positive patients with CKD than without (Supplementary Table 8).

The outcomes of patients without CKD summarised according to COVID-19 status (Table 2; Figures 1a & 2a), and of patients without COVID-19 summarised according to CKD status and eGFR (Supplementary Table 8; Supplementary Figures 3 & 4), are described in the Supplementary Results.
Discussion

In this multi-regional data-linkage study, we utilised a robust statistical approach combining multivariable outcome regression with propensity score weighting to evaluate the outcomes of ~87,000 patients with and without CKD tested for SARS-CoV-2. Overall, one-in-ten patients had a positive SARS-CoV-2 test. In patients with CKD, those with COVID-19 had a higher risk of cardiovascular and all-cause death than those without COVID-19 throughout follow-up, but especially within 30 days of SARS-CoV-2 testing. During this early period, patients with CKD and COVID-19 had a more than two-fold increased risk of cardiovascular death – and a more than four-fold increased risk of all-cause death – than CKD patients testing negative. Compared to patients without CKD, those with CKD were also more likely to test positive. Following a positive test, CKD patients had higher rates of cardiovascular complications, including hospitalisations, and cardiovascular death than those without CKD. Moreover, the risks of cardiovascular, COVID-19-related, and all-cause death increased as kidney function declined.

Our study has several strengths. First, its multi-regional design combined high-fidelity, high-quality Scottish linked healthcare data from patients undergoing community and hospital-based SARS-CoV-2 testing in three large NHS Health Boards (which together provide care for ~1.7 million people), irrespective of age, sex, socio-economic, kidney function, or hospitalisation status. Thus, the influence of case selection bias on our patient cohorts was minimised. Moreover, the accuracy and completion rates of the data sources used in this study were recently reported as 96% and 99%, respectively. Second, we utilised routinely-collected biochemistry data and criteria previously validated in electronic health records to determine baseline kidney function, reducing the potential for misclassification of CKD status. Third, our inclusion of control populations – COVID-19 negative patients and patients without CKD – alongside our use of a ‘doubly-robust’ estimator (concomitant multivariable outcome regression and weighting by the propensity score), limited the influence of confounding bias in our analyses.

Whilst the majority of patients with COVID-19 are considered to have increased cardiovascular risk, few studies have examined the nature or extent of this risk in patients with CKD. This is
important given the well-recognised association between cardiovascular disease and CKD.\textsuperscript{12, 13} Here, in \~14,000 non-hospitalised and hospitalised patients with CKD tested for SARS-CoV-2, we found that COVID-19 more than doubled the risk of cardiovascular death within 30 days, and by 57\% overall. Our secondary analysis showed that patients with COVID-19 and CKD had an increased risk of fatal and non-fatal myocardial infarction, heart failure and stroke compared to patients with COVID-19 but no CKD. In an adjusted model, CKD was also associated with a 64\% increased risk of cardiovascular death in patients with COVID-19. In contrast, Rao and colleagues investigated the risk of cardiovascular complications in patients with COVID-19 but found no increase in risk in patients with CKD compared to those without CKD.\textsuperscript{31} However, this study excluded non-hospitalised patients and patients who had tested negative for SARS-CoV-2, and relied on manual case note review to determine CKD status.

Our data add to the literature on COVID-19 outcomes in high-risk populations. However, a novel aspect of our approach is the inclusion of patients with CKD who tested negative for SARS-CoV-2. Of the few studies that have included such patients, all have identified COVID-19 as being strongly associated with a poor prognosis. Indeed, a recent meta-analysis found that COVID-19 increased the odds of death approximately six-fold in patients with CKD.\textsuperscript{32} This is more in-line with the risk of all-cause death we report in patients with CKD and COVID-19 at 30 days post-index test, consistent with the fact that most studies included in this meta-analysis reported in-hospital mortality only. Thus, our study is unique in reporting both short- \textit{and} medium-term patient outcomes. Our study is also less biased towards severe COVID-19 as we included both non-hospitalised and hospitalised patients, making our results more accurate, representative, and informative for patients with all severities of CKD and COVID-19.

We found that, compared to patients without CKD, those with CKD were more likely to test positive for COVID-19. Thereafter, patients with COVID-19 and CKD had higher rates of fatal and non-fatal myocardial infarction, heart failure and stroke, cardiovascular hospitalisations, and cardiovascular, COVID-19-related, and all-cause death than patients with COVID-19 but no CKD. Few studies have reported on all these aspects. Our data are consistent with reports of an increasing incidence
of COVID-19 as kidney function declines.\textsuperscript{33, 34} A number of factors likely contribute to this increased risk of COVID-19 in CKD, including case ascertainment bias (i.e. patients with CKD are more likely to be tested for SARS-CoV-2), greater viral exposure secondary to more frequent healthcare encounters (e.g. in-centre haemodialysis),\textsuperscript{11} and an underlying increased predisposition to infection due to altered immune response.\textsuperscript{35}

We recognise some limitations. First, our inability to account for selected variables (e.g. body mass index, smoking status, type of atrial fibrillation [i.e. paroxysmal \textit{versus} permanent; non-valvular or valvular]) means that we cannot exclude the potential for residual confounding. In addition, selected data relating to co-existing atrial fibrillation and prescribed cardiovascular medications were not available for patients included in Cohort 1. Second, rates of non-fatal cardiovascular complications, including atrial fibrillation and cardiovascular hospitalisations, may have been under-reported due to the competing risk of death in patients with COVID-19. Given the crude rates of non-fatal cardiovascular complications were generally higher in patients without COVID-19 suggests that this might be the case. We overcame this when evaluating cardiovascular and COVID-19-related death by calculating cause-specific hazard ratios from our regression models. Third, we excluded patients with no record of kidney function and those with only a single eGFR <60 ml/min/1.73 m\textsuperscript{2} during the biochemistry ‘lookback’ period. Consequently, young or less comorbid patients – who are less likely to have had their kidney function tested – may be relatively under-represented. Finally, those patients with CKD who tested negative for SARS-CoV-2 were a relatively ‘sick’ control group; their all-cause mortality was substantially higher than might be expected for the CKD population in general.\textsuperscript{36} One explanation for this is that SARS-CoV-2 PCR testing was largely restricted to the in-hospital setting for much of the early phase of the COVID-19 pandemic in the UK.\textsuperscript{37} To address this issue – and to illustrate the effect of including a more widely representative control group – we performed a sensitivity analysis restricted to those patients not hospitalised either in the week before or in the two weeks following their index COVID-19 test, and demonstrated a similar pattern of increased risk of cardiovascular and all-cause death in patients with COVID-19 compared to those without.
Conclusions
Our unique and comprehensive analysis suggests that COVID-19 significantly increases the risk of cardiovascular complications and death in patients with CKD, especially in the short-term. There is an urgent need to prioritise COVID-19 vaccination and cardiovascular risk reduction strategies in all patients with CKD.
Acknowledgements

Work relating to Cohort 1 was supported by DataLoch (www.dataloch.org), which is core-funded by the Data-Driven Innovation programme within the Edinburgh and South East Scotland City Region Deal (www.ddi.ac.uk). The authors would like to thank members of the DataLoch, eDRIS (Public Health Scotland) and Health Informatics Centre teams for their involvement in obtaining study approvals, provisioning and linking data, and the use of secure analytical platforms within each respective Safe Haven. The authors also wish to recognise the rapid work of the DataLoch COVID-19 Collaborative team which generated some of the data used in this paper (www.dataloch.org/node/155).

Role of the Funding Source

Cohort 1 of this study was funded by a special project award from the Scottish Funding Council Data-Driven Innovation Beacon Programme (PJG/RWH/ND). EL’s PhD is supported by The University of Dundee. PJG is supported by a Clinical Research Training Fellowship from the British Heart Foundation (FS/CRTF/20/24079). RWH is supported by a Fellowship from the Wellcome Trust (209562/Z/17/Z). ND is supported by a Senior Clinical Research Fellowship from the Chief Scientist Office (SCAF/19/02). SB is supported by The University of Dundee.

Conflicts of Interest

The authors have nothing to disclose.

Author contributions

EL, PJG, RWH, ND and SB conceived the study. PJG, RWH and ND contributed to the design and collection of data relating to Cohort 1; EL and SB contributed to the design and collection of data relating to Cohort 2. Data analysis was completed by EL and PJG. Interpretation and drafting of the manuscript were conducted by EL, PJG, ND and SB. All authors critically reviewed the manuscript and approved the final version.
Table Legends

Table 1. Clinical characteristics of patients included in Cohorts 1 and 2, grouped according to CKD and COVID-19 status.

Table 2. Outcomes of patients included in Cohorts 1 and 2, grouped according to CKD and COVID-19 status.
Figure Legends

**Figure 1.** Survival curves for cardiovascular (a) and all-cause (b) death according to COVID-19 status (i.e. positive *versus* negative) for patients with CKD (Panel A: Cohort 1; Panel C: Cohort 2) and patients without CKD (Panel B: Cohort 1; Panel D: Cohort 2). Note: y-axis scales are different for cardiovascular and all-cause death plots.

**Figure 2.** Forest plot summarising adjusted hazard ratios (HR) from Cohorts 1 and 2 and associated pooled meta-estimates for cardiovascular (a) and all-cause death (b) according to COVID-19 status (i.e. positive *versus* negative) for patients with CKD (red) and patients without CKD (blue) at 30 days (top panel), 90 days (middle panel) and to the end of study follow-up (bottom panel).
References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W and Lu R. A novel coronavirus from patients with pneumonia in China, 2019. *New England journal of medicine*. 2020.

2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B and Gu X. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The lancet*. 2020;395:1054-1062.

3. Drake TM, Riad AM, Fairfield CJ, Egan C, Knight SR, Pius R, Hardwick HE, Norman L, Shaw CA and McLean KA. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. *The Lancet*. 2021;398:223-237.

4. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D and Inglesby P. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020;584:430-436.

5. Bhaskaran K, Bacon S, Evans SJ, Bates CJ, Rentsch CT, MacKenna B, Tomlinson L, Walker AJ, Schultz A and Morton CE. Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. *The Lancet Regional Health-Europe*. 2021;6:100109.

6. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F and Carson G. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *bmj*. 2020;369.

7. Fried MW, Crawford JM, Mospan AR, Watkins SE, Munoz B, Zink RC, Elliott S, Burleson K, Landis C and Reddy KR. Patient characteristics and outcomes of 11 721 patients with coronavirus disease 2019 (COVID-19) hospitalized across the United States. *Clinical Infectious Diseases*. 2021;72:e558-e565.

8. Mehra MR, Desai SS, Kuy S, Henry TD and Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. *New England Journal of Medicine*. 2020;382:e102.

9. Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML and Wilson FP. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. *American Journal of Kidney Diseases*. 2021;77:190-203. e1.

10. Pakhchanian H, Raiker R, Mukherjee A, Khan A, Singh S and Chatterjee A. Outcomes of COVID-19 in CKD patients: a multicenter electronic medical record cohort study. *Clinical Journal of the American Society of Nephrology*. 2021;16:785-786.

11. Bell S, Campbell J, McDonald J, O’Neill M, Watters C, Buck K, Cousland Z, Findlay M, Lone NI and Metcalfe W. COVID-19 in patients undergoing chronic kidney replacement therapy and kidney transplant recipients in Scotland: findings and experience from the Scottish renal registry. *BMC nephrology*. 2020;21:1-12.

12. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, Matsushita K and Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *The Lancet*. 2013;382:339-352.

13. Matsushita K, Van der Velde M, Astor B, Woodward M, Levey A, De Jong P, Coresh J and Gansevoort R. Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. *Lancet*. 2010;375:2073-2081.

14. Harrison SL, Buckley BJ, Rivera-Caravaca JM, Zhang J and Lip GY. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. *European Heart Journal-Quality of Care and Clinical Outcomes*. 2021.

15. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J and Zhao Q. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. *JAMA cardiology*. 2020;5:802-810.

16. Sabatino J, De Rosa S, Di Salvo G and Indolfi C. Impact of cardiovascular risk profile on COVID-19 outcome. A meta-analysis. *PloS one*. 2020;15:e0237131.

17. Health Informatics Centre - Trusted Research Environment.
18. Government S. Scottish Index of Multiple Deprivation 2020. 2020.
19. Norton JM, Ali K, Jurkowitz CT, Kiryluk K, Park M, Kawamoto K, Shang N, Navaneethan SD, Narva AS and Drawz P. Development and validation of a pragmatic electronic phenotype for CKD. *Clinical Journal of the American Society of Nephrology*. 2019;14:1306-1314.
20. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, Kusek JW, Eggers P, Van Lente F and Greene T. A new equation to estimate glomerular filtration rate. *Annals of internal medicine*. 2009;150:604-612.
21. Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, Stevens P, Bilous R, Lamb E and Coresh J. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int*. 2013;3:5-14.
22. Scottish Care Information Diabetes Collaboration.
23. Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA and Davidian M. Doubly robust estimation of causal effects. *American journal of epidemiology*. 2011;173:761-767.
24. Williams B and Zhang Y. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. *The Lancet*. 2020;395:1671-1673.
25. Thng ZX, De Smet MD, Lee CS, Gupta V, Smith JR, McCluskey PJ, Thorne JE, Kempen JH, Zierhut M and Nguyen QD. COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. *British Journal of Ophthalmology*. 2021;105:306-310.
26. Scotland NNS. NHS National Services Scotland (NSS) Information and Intelligence assessment of SMR01 data 2014-2015. 2015;2021.
27. Scotland NPH. Data Support and Monitoring: SMR Completeness Estimates. 2021;2021.
28. Li X and Shen C. Doubly robust estimation of causal effect: upping the odds of getting the right answers. *Circulation: Cardiovascular Quality and Outcomes*. 2020;13:e006065.
29. Linschoten M, Peters S, van Smeden M, Jewbali LS, Schaap J, Siebelink H-M, Smits PC, Tieleman RG, van der Harst P, van Gilst WH and Asselbergs FW. Cardiac complications in patients hospitalised with COVID-19. *European Heart Journal: Acute Cardiovascular Care*. 2020;9:817-823.
30. Podesta MA, Valli F, Galassi A, Cassia MA, Ciceri P, Barbieri L, Carugo S and Cozzolino M. COVID-19 in Chronic Kidney Disease: The Impact of Old and Novel Cardiovascular Risk Factors. *Blood Purif*. 2021;50:740-749.
31. Roe A, Ranka S, Ayers C, Hendren N, Rosenblatt A, Alger HM, Rutan C, Omar W, Khera R, Gupta K, Mody P, DeFilippi C, Das SR, Hedayati SS and de Lemos JA. Association of Kidney Disease With Outcomes in COVID-19: Results From the American Heart Association COVID-19 Cardiovascular Disease Registry. *J Am Heart Assoc*. 2021;10:e020910.
32. Cai R, Zhang J, Zhu Y, Liu L, Liu Y and He Q. Mortality in chronic kidney disease patients with COVID-19: a systematic review and meta-analysis. *International Urology and Nephrology*. 2021;1-7.
33. Chung EYM, Palmer SC, Natale P, Krishnan A, Cooper TE, Saglimbene VM, Ruospo M, Au E, Jayanti S, Liang A, Jie Deng DJ, Chui J, Higgins GY, Tong A, Wong G, Teixeira-Pinto A, Hodson EM, Craig JC and Strippoli GFM. Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis. *Am J Kidney Dis*. 2021.
34. Gibertoni D, Reno C, Rucci P, Fantini MP, Buscaroli A, Mosconi G, Rigotti A, Giudicissi A, Mambelli E, Righini M, Zambianchi L, Santoro A, Bravi F and Altini M. COVID-19 incidence and mortality in non-dialysis chronic kidney disease patients. *PLoS One*. 2021;16:e0254525.
35. Syed-Ahmed M and Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. *Advances in chronic kidney disease*. 2019;26:8-15.
36. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F and Garg AX. Chronic kidney disease and mortality risk: a systematic review. *Journal of the American Society of Nephrology*. 2006;17:2034-2047.
37. Wallis G, Siracusas F, Blank M, Painter H, Sanchez J, Salinas K, Mamuyac C, Marudamuthu C, Wrigley F and Corrah T. Experience of a novel community testing programme for COVID-19 in London: lessons learnt. *Clinical Medicine*. 2020;20:e165.
Table 1. Clinical characteristics of patients included in Cohorts 1 and 2, grouped according to CKD and COVID-19 status.

|                  | COHORT 1 |                  | COHORT 2 |                  |                  |
|------------------|----------|------------------|----------|------------------|------------------|
|                  | CKD      | No CKD           | CKD      | No CKD           |                  |
| Number of patients, n | 734 (11) | 2,997 (12)       | 865 (11) | 21,632 (12)      |                  |
| Age, years       | 81 (11)  | 59 (21)          | 84 (10)  | 59 (20)          |                  |
| Sex              |          |                  |          |                  |                  |
| Women            | 384 (52.3) | 2,764 (45.0) | 502 (58.0) | 7,373 (45.0)     |                  |
| Men              | 350 (47.7) | 2,355 (55.0) | 363 (42.0) | 2,959 (55.0)     |                  |
| SIMD quintile    |          |                  |          |                  |                  |
| 1 (most deprived)| 103 (14.0) | 616 (12.0)       | 162 (18.7) | 1,160 (18.7)     |                  |
| 2                | 207 (28.2) | 1,280 (25.0)     | 185 (21.4) | 1,391 (21.4)     |                  |
| 3                | 113 (15.4) | 920 (18.0)       | 182 (21.0) | 1,491 (21.0)     |                  |
| 4                | 112 (15.3) | 889 (17.4)       | 216 (25.0) | 1,977 (25.0)     |                  |
| 5 (least deprived)| 198 (27.0) | 1,404 (27.4)     | 120 (13.9) | 1,317 (18.0)     |                  |
| Co-existing medical conditions |          |                  |          |                  |                  |
| Angina           | 91 (12.4) | 571 (11.2)       | 69 (8.0)  | 533 (7.3)        |                  |
| Atrial fibrillation* | -         | -                | 207 (23.9) | 1,444 (17.7)     |                  |
| Myocardial infarction | 124 (16.9) | 807 (15.8)     | 91 (10.5)  | 744 (10.1)       |                  |
| Heart failure    | 196 (26.7) | 1,152 (22.5)    | 133 (15.4) | 847 (11.5)       |                  |
| Stroke           | 127 (17.3) | 704 (13.8)       | 123 (14.2) | 671 (9.1)        |                  |
| Diabetes         | 275 (37.5) | 1,819 (35.5)     | 277 (32.0) | 2,388 (32.6)     |                  |
| Cancer           | 159 (21.7) | 1,372 (26.8)     | 98 (11.3)  | 858 (11.7)       |                  |
| Chronic lower respiratory disease | 223 (30.4) | 1,418 (27.7) | 232 (26.8) | 1,877 (25.6)     |                  |
| Chronic liver disease | 27 (3.7)  | 213 (4.2)        | 21 (2.4)  | 171 (2.3)        |                  |
| Renal history    |          |                  |          |                  |                  |
| Kidney failure   | 35 (4.8)  | 302 (5.9)        | 29 (3.4)  | 211 (2.9)        |                  |
| Baseline eGFR    | 40 (14)   | 42 (14)          | 43 (12)   | 44 (12)          |                  |
| Baseline eGFR category |          |                  |          |                  |                  |
| ≥90              | -         | -                | -         | -                |                  |
| 60 – 89          | -         | -                | -         | -                |                  |
| 45 – 59          | 314 (42.8) | 2,394 (46.8)     | 436 (50.4) | 3,828 (52.2)     |                  |
| 30 – 44          | 236 (32.2) | 1,632 (31.9)     | 270 (31.2) | 2,279 (31.1)     |                  |
| 15 – 29          | 118 (16.1) | 669 (13.1)       | 105 (12.1) | 809 (11.0)       |                  |
| Current medication                      | ≤15   |  66 (9.0) | 424 (8.3) | -     | -     | 54 (6.2) | 420 (5.7) | -     | -     |
|----------------------------------------|-------|-----------|-----------|-------|-------|-----------|-----------|-------|-------|
| ACE-inhibitor or ARB                   | 263   | (35.8)    | 2,126     | (41.5)| 674   | (22.5)    | 5,959     | (21.2)| 218   | (25.2) |
| Aspirin*                               | 2,126 | -         | -         | -     | 157   | (18.1)    | 1,599     | (21.8)| 299   | (8.1)  |
| Other antiplatelet agent*              | 2,126 | -         | -         | -     | 128   | (14.8)    | 861       | (11.7)| 247   | (6.7)  |
| Beta-blockers*                         | 2,126 | -         | -         | -     | 300   | (34.7)    | 2,655     | (36.2)| 497   | (13.5) |
| Immunosuppressants                     | 201   | (3.9)     | 66 (2.2)  | 566   | (2.0) | 11 (1.3)  | 151 (2.1) |       | 13    | (0.4)  |
| Loop diuretic*                         | 27    | (3.7)     | 66 (2.2)  | 566   | (2.0) | 303 (35.0)| 2,312     | (31.5)| 264   | (7.1)  |
| Mineralocorticoid receptor antagonist* | -     | -         | -         | -     | 66    | (7.6)     | 558 (7.6) |       | 64    | (1.7)  |
| Novel oral anticoagulant*              | -     | -         | -         | -     | 142   | (16.4)    | 1,136     | (15.5)| 154   | (4.2)  |
| Warfarin*                              | -     | -         | -         | -     | 43    | (5.0)     | 499 (6.8) |       | 45    | (1.2)  |

Values are mean ± SD, n (%), or median [interquartile range]. Abbreviations: ACE – angiotensin converting enzyme; ARB – angiotensin receptor blocker; CKD – chronic kidney disease (please refer to Methods section for definition of CKD status); eGFR – estimated glomerular filtration rate (ml/min/1.73 m²); SIMD – Scottish index of multiple deprivation. *data not available for Cohort 1.
Table 2. Outcomes of patients included in Cohorts 1 and 2, grouped according to CKD and COVID-19 status.

|                  | COHORT 1 |          | COHORT 1 |          | COHORT 2 |          | COHORT 2 |          |
|------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                  | CKD      | No CKD   | CKD      | No CKD   | CKD      | No CKD   | CKD      | No CKD   |
|                  | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
| Number of patients, n | 734      | 5,119    | 2,997    | 28,054   | 865      | 7,336    | 3,691    | 38,168   |
| Primary outcomes  |          |          |          |          |          |          |          |          |
| Cardiovascular death |          |          |          |          |          |          |          |          |
| 30 days           | 57 (7.8) | 172 (3.4) | 57 (1.9) | 254 (0.9) | 62 (7.2) | 254 (3.5) | 55 (1.5) | 316 (0.8) |
| 90 days           | 72 (9.8) | 290 (5.7) | 68 (2.3) | 377 (1.3) | 72 (8.3) | 453 (6.2) | 70 (1.9) | 515 (1.3) |
| End of study follow-up | 86 (11.7) | 426 (8.3) | 86 (2.9) | 542 (1.9) | 92 (10.6) | 730 (10.0) | 94 (2.5) | 840 (2.2) |
| COVID-19-related death |          |          |          |          |          |          |          |          |
| 30 days           | 250 (34.1) | -         | 377 (12.6) | -         | 295 (34.1) | -         | 397 (10.8) | -         |
| 90 days           | 267 (36.4) | -         | 404 (13.5) | -         | 313 (36.2) | -         | 423 (11.5) | -         |
| End of study follow-up | 270 (36.8) | -         | 407 (13.6) | -         | 318 (36.8) | -         | 427 (11.6) | -         |
| All-cause death   |          |          |          |          |          |          |          |          |
| 30 days           | 260 (35.4) | 442 (8.6) | 399 (13.3) | 974 (3.5) | 302 (34.9) | 642 (8.8) | 405 (11.0) | 1,025 (2.7) |
| 90 days           | 304 (41.4) | 803 (15.7) | 473 (15.8) | 1,702 (6.1) | 342 (39.5) | 1,157 (15.8) | 466 (12.6) | 1,782 (4.7) |
| End of study follow-up | 346 (47.1) | 1,246 (24.3) | 541 (18.1) | 2,688 (9.6) | 397 (45.9) | 1,880 (25.6) | 547 (14.8) | 3,007 (7.9) |
| Secondary outcomes |          |          |          |          |          |          |          |          |
| Fatal/non-fatal myocardial infarction |          |          |          |          |          |          |          |          |
| 30 days           | 7 (1.0) | 132 (2.6) | 8 (0.3) | 254 (0.9) | 9 (1.0) | 154 (2.1) | NA | 386 (1.0) |
| 90 days           | 8 (1.1) | 155 (3.0) | 9 (0.3) | 293 (1.0) | 9 (1.0) | 193 (2.6) | 9 (0.2) | 428 (1.1) |
| End of study follow-up | 11 (1.5) | 190 (3.7) | 15 (0.5) | 351 (1.3) | 13 (1.5) | 248 (3.4) | 11 (0.3) | 505 (1.3) |
| Fatal myocardial infarction |          |          |          |          |          |          |          |          |
| End of study follow-up | NA | 62 (1.2) | NA | 74 (0.3) | 7 (0.8) | 113 (1.5) | 10 (0.3) | 142 (0.4) |
| Fatal/non-fatal heart failure |          |          |          |          |          |          |          |          |
| 30 days           | 16 (2.2) | 117 (2.3) | NA | 133 (0.5) | 21 (2.4) | 348 (4.7) | 6 (0.2) | 362 (0.9) |
| 90 days           | 21 (2.9) | 168 (3.3) | 8 (0.3) | 166 (0.6) | 23 (2.7) | 423 (5.8) | 8 (0.2) | 414 (1.1) |
| End of study follow-up | 24 (3.3) | 226 (4.4) | 10 (0.3) | 212 (0.8) | 28 (3.2) | 496 (6.8) | 14 (0.4) | 478 (1.3) |
| Fatal heart failure |          |          |          |          |          |          |          |          |
| End of study follow-up | 18 (2.5) | 88 (1.7) | NA | 60 (0.2) | 20 (2.3) | 182 (2.5) | 11 (0.3) | 93 (0.2) |
| Fatal/non-fatal stroke |          |          |          |          |          |          |          |          |
| 30 days           | 10 (1.4) | 96 (1.9) | 18 (0.6) | 348 (1.2) | 15 (1.7) | 249 (3.4) | 31 (0.8) | 574 (1.5) |
| 90 days           | 13 (1.8) | 121 (2.4) | 23 (0.8) | 415 (1.5) | 19 (2.2) | 294 (4.0) | 38 (1.0) | 648 (1.7) |
| Event                              | 30 days | 90 days | End of follow-up |
|------------------------------------|---------|---------|------------------|
| **Fatal stroke**                   |         |         |                  |
| End of study follow-up             | 16 (2.2)| 28 (0.9)| 25 (2.9)         |
| 16 (2.2)                           | 158 (3.1)| 487 (1.7)| 348 (4.7)       |
| 25 (2.9)                           | 44 (1.2)        | 744 (1.9)      |
| **Fatal/non-fatal pulmonary embolism** |         |         |                  |
| End of study follow-up             | 6 (0.8) | 14 (0.5)| NA               |
| 14 (0.5)                           | 57 (1.1)       | NA            | 410 (1.1)        |
| **Fatal pulmonary embolism**       |         |         |                  |
| End of study follow-up             | NA      | 15 (0.5)| 7 (0.8)          |
| 15 (0.5)                           | 286 (1.0)      | 87 (1.2)       | 17 (0.5)         |
| 7 (0.8)                            | 17 (0.5)       | 370 (1.0)      |
| **Atrial fibrillation hospitalisations** |       |         |                  |
| 30 days                            | NA      | 225 (4.4)| 557 (2.0)       |
| 12 (1.6)                           | 292 (5.7)      | 676 (2.4)      | 435 (5.9)        |
| 15 (2.0)                           | 54 (7.4)       | 105 (3.5)      | 60 (6.9)         |
| **Cardiovascular hospitalisations** |         |         |                  |
| 30 days                            | 28 (3.8) | 630 (12.3)| 1,847 (6.6)     |
| 12 (1.6)                           | 292 (5.7)      | 676 (2.4)      | 435 (5.9)        |
| 15 (2.0)                           | 54 (7.4)       | 105 (3.5)      | 60 (6.9)         |
| **All hospitalisations**           |         |         |                  |
| 30 days                            | 274 (37.3)| 2,928 (57.2)| 13,361 (47.6)   |
| 12 (1.6)                           | 292 (5.7)      | 676 (2.4)      | 435 (5.9)        |
| 15 (2.0)                           | 54 (7.4)       | 105 (3.5)      | 60 (6.9)         |
| **End of follow-up**               | 896 (29.9)| 15,767 (56.2)| 5,063 (69.0)    |
| **Length of stay**                 | 7 [3, 18] | 17 (7) | 5 [2, 15] |

Values are median [interquartile range] or n (%). NAs represent potentially identifiable or count data <5, redacted in order to protect patient confidentiality.
### A – Cardiovascular death

|                  | HR    | lower | upper |
|------------------|-------|-------|-------|
| **CKD – 30 days**|       |       |       |
| Cohort 1         | 2.44  | 1.80  | 3.32  |
| Cohort 2         | 2.16  | 1.42  | 3.28  |
| **Summary**      | 2.34  | 1.83  | 2.99  |
| **Non–CKD – 30 days**|       |       |       |
| Cohort 1         | 1.91  | 1.42  | 2.59  |
| Cohort 2         | 1.96  | 1.26  | 3.06  |
| **Summary**      | 1.93  | 1.50  | 2.47  |
| **CKD – 90 days**|       |       |       |
| Cohort 1         | 1.91  | 1.47  | 2.49  |
| Cohort 2         | 1.43  | 1.02  | 2.01  |
| **Summary**      | 1.71  | 1.39  | 2.11  |
| **Non–CKD – 90 days**|       |       |       |
| Cohort 1         | 1.59  | 1.21  | 2.07  |
| Cohort 2         | 1.49  | 1.04  | 2.14  |
| **Summary**      | 1.55  | 1.25  | 1.93  |
| **CKD – study end**|       |       |       |
| Cohort 1         | 1.83  | 1.44  | 2.32  |
| Cohort 2         | 1.27  | 0.96  | 1.69  |
| **Summary**      | 1.57  | 1.31  | 1.89  |
| **Non–CKD – study end**|       |       |       |
| Cohort 1         | 1.54  | 1.21  | 1.95  |
| Cohort 2         | 1.26  | 0.94  | 1.70  |
| **Summary**      | 1.42  | 1.18  | 1.71  |

### B – All-cause death

|                  | HR    | lower | upper |
|------------------|-------|-------|-------|
| **CKD – 30 days**|       |       |       |
| Cohort 1         | 4.66  | 3.99  | 5.46  |
| Cohort 2         | 4.24  | 3.43  | 5.39  |
| **Summary**      | 4.53  | 3.97  | 5.16  |
| **Non–CKD – 30 days**|       |       |       |
| Cohort 1         | 4.16  | 3.68  | 4.69  |
| Cohort 2         | 4.61  | 3.69  | 5.77  |
| **Summary**      | 4.26  | 3.83  | 4.74  |
| **CKD – 90 days**|       |       |       |
| Cohort 1         | 3.14  | 2.74  | 3.59  |
| Cohort 2         | 2.73  | 2.26  | 3.31  |
| **Summary**      | 3.01  | 2.68  | 3.35  |
| **Non–CKD – 90 days**|       |       |       |
| Cohort 1         | 2.96  | 2.66  | 3.29  |
| Cohort 2         | 3.12  | 2.61  | 3.72  |
| **Summary**      | 3.00  | 2.74  | 3.29  |
| **CKD – study end**|       |       |       |
| Cohort 1         | 2.57  | 2.27  | 2.91  |
| Cohort 2         | 2.14  | 1.83  | 2.51  |
| **Summary**      | 2.41  | 2.17  | 2.64  |
| **Non–CKD – study end**|       |       |       |
| Cohort 1         | 2.27  | 2.06  | 2.50  |
| Cohort 2         | 2.24  | 1.94  | 2.59  |
| **Summary**      | 2.26  | 2.09  | 2.45  |
APPENDIX

Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study

Emilie J. Lambourg*, PharmD,1 Peter J. Gallacher*, MBChB MPH,2 Robert W. Hunter, MBChB PhD,2,3 Moneeza Siddiqui, PhD,1 James Chalmers, MBChB PhD,4 Dan Pugh, MBChB,3 Neeraj Dhaun†, MBChB PhD,2,3 Samira Bell†, MBChB MD1.

1 Division of Population Health and Genomics, University of Dundee, Dundee, UK
2 BHF/University Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK
3 Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK
4 Department of Molecular and Clinical Medicine, University of Dundee, Dundee, UK
5 Scottish Renal Registry, Scottish Health Audits, Public Health & Intelligence, Glasgow, UK

*These authors contributed equally
†These authors contributed equally

Non-standard abbreviations

CHI – Community Health Index (number)
ICD – International Classification of Diseases
NRS – National Records for Scotland
SIMD – Scottish Index of Multiple Deprivation
SMR01 – Scottish Morbidity Record 01
Supplementary Methods

Study cohorts

Cohort 1

All patients who had a SARS-CoV-2 test in the NHS Lothian Health Board between February 1, 2020, and March 31, 2021 were identified. Positive and negative COVID-19 episodes were linked with regional electronic patient and biochemistry records (TrakCare software application, InterSystems Corporation, Cambridge, MA, USA) and national hospitalisation (Scottish Morbidity Record 01, Information Services Division, Scotland), dispensed community prescription (Prescribing Information System, Information Services Division, Scotland) and death records (National Records of Scotland, Scotland) within the DataLoch Repository and Safe Haven (University of Edinburgh/NHS Lothian, Edinburgh, Scotland).

Cohort 2

All patients who had had a measure of serum creatinine in the NHS Fife or Tayside Health Boards since April 1, 2009, and subsequently had a SARS-CoV-2 test between February 28, 2020, and February 8, 2021, were identified. Positive and negative COVID-19 episodes were defined as for Cohort 1 before being linked with national hospitalisation (Scottish Morbidity Record 01, Information Services Division, Scotland), dispensed community prescription (Prescribing Information System, Information Services Division, Scotland), and death records (National Records of Scotland, Scotland) within the Health Informatics Centre Safe Haven (University of Dundee/NHS Fife and Tayside, Dundee, Scotland).^{17}

Data sources

Scottish Morbidity Record 01 (SMR01)

The Scottish Morbidity Record 01 (SMR01) general / acute inpatient and day case is an episode-based hospitalisation record, indexed by community health index (CHI) number, capturing all hospitalisations from non-obstetric and non-psychiatric specialties from all residents in Scotland. SMR01 are routinely collected healthcare data of high-quality in terms of consistency and national coverage. To ensure its quality, a set of validation rules is applied to all SMR01 data before release.(1) Across all SMR01
records, estimated completion and accuracy rates are 99% and 89%, respectively. For SMR01 records relating to cardiovascular diagnoses, the accuracy rate is 94.2%.(2)

Information contained in SMR01 data includes: date of admission and discharge date, admission type and where the episode took place, patient’s conditions (ICD-10 coded) and interventions received (OPCS-4 coded). Up to 6 diagnoses are available to describe patients’ conditions (main and five additional reasons for admission). All 6 positions were searched for presence of at least one relevant ICD-10 code over a 5-year look-back period prior to the index date to assess patient’s baseline comorbidities. However, only the first 2 positions were searched to characterise cardiovascular hospitalisations occurring on or after the index date. Previously conducted sensitivity analyses validated the accuracy of restricting diagnosis coding to the first 2 out of 6 positions to ensure an optimal balance of diagnostic coding specificity and sensitivity.(3) Further information regarding SMR01 data is available on the website of the Information Services Division (National Services Scotland, NHS Scotland): https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=5

National Records of Scotland (NRS) Death Records

The NRS is a CHI-indexed dataset covering all deaths in Scotland. Information on the death status, date of death, and causes of death were extracted and linked to the other records of patients tested for SARS-CoV-2 via their unique CHI number. Up to eleven different causes of death (the underlying cause and up to 10 additional causes) based on the amended cause of death text are recorded in the NRS data and coded using the ICD-10 classification. Besides the underlying cause, the additional causes of death are factors, diseases or injury that have contributed in some way to the occurrence of the death.(4) All positions were searched for relevant ICD-codes to identify COVID-19 related deaths whilst only the first two positions were considered to assess cardiovascular mortality. More information on the NRS data is
available on the website of the Information Services Division (National Services Scotland, NHS Scotland): [https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=13](https://www.ndc.scot.nhs.uk/National-Datasets/data.asp?SubID=13)

*The Scottish Renal Registry (SRR)*

For the Tayside/Fife cohort, patients on chronic renal replacement therapy (RRT) were identified from the SRR. The SRR was established in 1991 with data backfilled to 1960 from European Renal Association-European Dialysis and Transplant Association (ERA-EDTA). It is a national registry of all patients receiving RRT (haemodialysis, peritoneal dialysis or kidney transplant) for end-stage kidney disease in Scotland, indexed by CHI number. The SRR has 100% unit and patient coverage. Data held by the registry include patient demographics, full RRT history, primary renal diagnosis (using ERA-EDTA codes) and monthly linkage with National Health Service Blood and Transplant (NHS BT) for transplant status. More information is available on the SRR website: [https://www.srr.scot.nhs.uk/](https://www.srr.scot.nhs.uk/)

*The Scottish Care Information – Diabetes (SCI-D) database*

The SCI-D is a CHI-indexed high-quality integrated database containing clinical information on over 99% of people with diagnosed diabetes in Scotland.(5) It is automatically updated from primary and secondary care systems, with almost all practices in Scotland participating in data collection. The dataset was used here as a population-based diabetes register since only the diagnosis date was extracted to identify all patients with a diagnosis of diabetes made prior to their index date.

*Community prescribing*

Medications prescribed over the 6-month period prior to the index date were used to determine presence of a baseline exposure to ACE-inhibitor/ARB, immunosuppressants or presence of a chronic respiratory disease in patients included in the cohort. The identification of a single relevant BNF code (see [Supplementary Text 1](#)) was necessary and sufficient to identify the comorbidity or drug exposure.

* Determination of patient demographics, CKD status, comorbidities, causes of death and history of prescribed medications

*Patient demographics*
For both study cohorts, patient age, sex and social deprivation status were determined from linked hospitalisation records. Social deprivation status was defined according to the Scottish Index of Multiple Deprivation (SIMD) – a validated measure of social deprivation determined by factors related to residential address (zip code) (Appendix). (6) Patients were assigned an individual SIMD rank at the time of their index SARS-CoV-2 test. Based on these ranks, patients were assigned a SIMD quintile, where the first and fifth quintiles were considered the most and least deprived, respectively. (7)

**Chronic kidney disease**

Both study cohorts utilised the same criteria – validated in electronic health records and based on the timing and nature of prior serum creatinine results – to determine CKD status at the time of index SARS-CoV-2 test. (8) For patients included in Cohort 1, two years of prior serum creatinine data were used to inform CKD status using these criteria. For patients included in Cohort 2, all historic serum creatinine results dating back to April 1, 2009, were available for analysis.

In brief, eGFRs were calculated for all assay-corrected serum creatinine results using the Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration equation. (9) CKD was defined when a patient’s most recent eGFR was <60 ml/min/1.73m² and at least one value obtained >90 days prior was also calculated as <60 ml/min/1.73m². Using the eGFR value closest to the index date for each patient, CKD stage was classified according to Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. (10) Patients with kidney failure requiring kidney replacement therapy (i.e. haemodialysis, peritoneal dialysis or kidney transplantation) were identified from record linkage with regional or national renal registries (Cohort 1 – VitalData; Cohort 2 – Scottish Renal Registry). Those patients with only a single measure of eGFR <60 ml/min/1.73m² prior to their index test were excluded from further analysis (Supplementary Figure 1).

**Comorbidities and causes of death**

Patient comorbidities were defined from International Classification of Diseases (ICD) codes associated with hospitalisations during a 5-year ‘lookback’ period prior to the index SARS-CoV-2 test. For every
index COVID-19 episode identified in Cohorts 1 and 2, the following comorbidity data were extracted from linked hospitalisation records: (history of) angina, cancer, chronic liver disease, chronic lower respiratory disease, heart failure, myocardial infarction, and stroke. For Cohort 2, data relating to co-existing atrial fibrillation were also available. In addition, diabetes status was obtained via record linkage with a national diabetes registry (Scottish Care Information – Diabetes Collaboration).(11) Causes of death were determined following the identification of relevant ICD codes in linked National Records of Scotland death records.

History of prescribed medications

Anatomical Therapeutic Chemical (ATC) and British National Formulary (BNF) codes were used to identify dispensed prescriptions of angiotensin converting enzyme inhibitors or angiotensin receptor blockers (ACE-inhibitors/ARBs) and immunosuppressants in the community prescribing records of individual patients during the 6 months preceding their index SARS-CoV-2 test. For patients included in Cohort 2, prescription data relating to common cardiovascular medications (i.e. ACE-inhibitor, angiotensin receptor blockers, aspirin, antiplatelet agents, beta-blockers, loop diuretics, mineralocorticoid receptor antagonists, novel oral anticoagulants and warfarin) dispensed during the 6 months preceding each index SARS-CoV-2 test were also available.

Statistical analysis

Covariate-balanced propensity scoring and regression modelling

For our primary analysis, we sought to estimate the causal effect of COVID-19 on outcomes in patients with and without CKD, whilst for our secondary analysis, we sought to estimate the causal effect of CKD on outcomes in patients with and without COVID-19. With the aim of obtaining an unconfounded estimate, we utilised a ‘doubly-robust’ estimator with bootstrapped standard errors and 95% confidence intervals for the primary outcome analyses (Appendix).(12) This approach combines a multivariable outcome regression model with weighting by the covariate-balanced propensity score (CBPS). A key
strength of this method is that an unbiased effect estimate can still be obtained, even if one of the component models (either the outcome regression or CBPS model) has been mis-specified.\textsuperscript{12, 13}

For the primary analysis, Cox regression was used to explore the association between COVID-19 status (the primary exposure) and cardiovascular and all-cause death (the primary outcomes). For the secondary analysis, Cox regression was used to explore the association between CKD status (the primary exposure) and cardiovascular, COVID-19 and all-cause death (the primary outcomes). For cardiovascular and COVID-19-related death, cause-specific hazard ratios were calculated to account for the competing risks of death from non-cardiovascular causes and death from non-COVID-19 causes, respectively.

For each analysis, we initially ran an unadjusted model before combining CBPS weighting and adjustment for several known confounders in a fully adjusted model. Using CBPS, covariates were balanced between exposure groups (COVID-19 and CKD status) in patients with and without CKD, and in patients with and without COVID-19 for the primary and secondary analyses, respectively.\textsuperscript{14} Confounders were specified \textit{a priori} and included age, sex, social demographic status, comorbidities (history of angina, myocardial infarction, heart failure, stroke, diabetes, cancer, chronic respiratory disease, chronic liver disease) and selected current medication (ACE-inhibitors/ARBs, immunosuppressant therapy) based on their potential relevance to COVID-19 outcomes.\textsuperscript{15, 16}

For each primary outcome, hazard ratios derived from CBPS-weighted, fully-adjusted multivariable models in individual cohorts were pooled to obtain an overall meta-estimate. Both cohorts utilised similar patient populations based in the same country, whilst the design, definitions and overall methodology employed in each study cohort were also similar. Consequently, meta-estimates were computed using a fixed-effects model.

Thereafter, Cox regression models adjusting for the same confounders as before but with no CBPS-weighting were used to estimate the association between eGFR (primary exposure) and the risk of
cardiovascular, all-cause, and COVID-19-related death in patients with and without COVID-19. For this analysis, eGFR was modelled as a continuous variable with restricted cubic splines using knots placed at the 5th, 25th, 50th and 75th centiles of eGFR measures in each cohort, as described previously.\(^{(17)}\)

Unadjusted and CBPS-weighted, multivariable Cox models were generated and fitted using the cobalt, rms, survival, and WeightIt packages, whilst meta-estimates were obtained using the meta package. All data were analysed using the R statistical programming language (Version 3.6.2, Vienna, Austria).

**Missing data**

Age, sex, comorbidity, prescribing, and outcome data were complete for all patients in both study cohorts. In Cohort 1, data relating to kidney function and social deprivation status were missing in 13.2% and 0.7% of all patient records, respectively. These were excluded from further analysis. In Cohort 2, data relating to social deprivation status were missing in 5.1%. For these records, hot deck imputation was implemented, with missing SIMD quintiles replaced by the observed value of another individual randomly chosen from all patients sharing a similar zip code.

**Ethical (IRB) approval and statement of data transparency**

The study was performed with the approvals of local Research Ethics Committees and delegated Caldicott Guardians for the NHS Fife, Lothian, and Tayside Health Boards, in accordance with the Declaration of Helsinki. All study methods and results were described and reported according to STROBE guidelines.\(^{(18)}\) Data provision and linkage were carried out by the DataLoch (University of Edinburgh/NHS Lothian, [https://www.dataloch.org/](https://www.dataloch.org/)) and University of Dundee Health Informatics Centre (HIC, [https://www.dundee.ac.uk/hic](https://www.dundee.ac.uk/hic)) within ISO27001 and Scottish Government accredited secure Safe Havens for Cohorts 1 and 2, respectively. HIC Standard Operating Procedures have been reviewed and approved by the NHS East of Scotland Research Ethics Service and consent was obtained from the NHS Fife Caldicott Guardian. Patient consent was not sought as the study utilised fully-anonymised data. To minimise the risk of disclosure, only summary data were extracted from each Safe Haven.
Individual-level data are available *via* application to the DataLoch and Health Informatics Centre. Our analysis code is publicly available [here](#).
Supplementary Results

Baseline characteristics of patients without CKD according to COVID-19 status
In patients without CKD, differences in baseline characteristics according to COVID-19 status were less marked across both cohorts (Table 1). In patients who tested positive and negative, the proportion of women, rates of cardiovascular comorbidity and drug prescriptions, and eGFR were all similar.

Baseline characteristics of patients with COVID-19 according to CKD status
A positive SARS-CoV-2 test was more likely in patients with CKD than in those without CKD (Cohort 1: 12.5% versus 9.7%; Cohort 2: 10.5% versus 8.8%). In patients with COVID-19, those with CKD were older and had a greater burden of cardiovascular comorbidity than patients without CKD (Supplementary Table 4). The differences between patients with and without CKD were as marked in those without COVID-19.

Outcomes of patients without CKD according to COVID-19 status
In patients without CKD, the adjusted risk of cardiovascular death at 30 days was increased two-fold in patients with COVID-19 compared to patients testing negative (csHR meta-estimate 1.94, 95% CI 1.52 to 2.47) (Table 2; Figures 1a & 2a). By the end of study follow-up, the adjusted risk of cardiovascular death in positive versus negative patients without CKD had reduced (csHR meta-estimate 1.42, 95% CI 1.19 to 1.70). A similar pattern was evident for the risk of all-cause death in these patients (Table 2; Figures 1b & 2b).

Outcomes of patients without COVID-19 according to CKD status and eGFR
Across both cohorts, significant differences in outcomes between those with and without CKD were also evident in patients without COVID-19. CKD was associated with an increased risk of cardiovascular death (csHR meta-estimate 1.46, 95% CI 1.33 to 1.60) and all-cause death (csHR meta-estimate 1.24, 95% CI 1.18 to 1.31) (Supplementary Table 6; Supplementary Figures 3 & 4). Finally, CKD was also
associated with higher rates of cardiovascular complications and subsequent hospitalisations in these patients.
**Supplementary Text 1.** List of International Classification of Diseases and BNF codes employed in study.

| Condition                        | ICD-10 Code                  |
|----------------------------------|-----------------------------|
| **Cancer**                       | *ICD-10* Any “C” code        |
| **Chronic liver disease**        | B18, K70, K74.3, K74.4, K74.5, K74.6, I85.0, I85.9, I98.2, I98.3, K76, R18, Z94.4, K72.1, K71.3, K71.4, K71.5, K71.7 |
| **Chronic respiratory disease**  | I27.8, I27.9 J40-45, J46, J47, J60-67, J68.4, J70.1, J70.3 |
| **COVID-19**                     | *ICD-10* U071, U072          |
| **Cardiovascular diagnoses**     | *ICD-10 Code*                |
| Angina                           | I201, I208, I209             |
| Heart failure                    | I11.0, I13.0, I13.2, I50     |
| Myocardial infarction            | I21, I22, I23, I241, I252    |
| Stroke                           | G45, G46, I60-69             |
| Pulmonary embolism               | I26.0, I26.9                |

| Community prescription data     | **ATC Code**                |
| Exposure to ACE-inhibitor/ARB   | ATC C09AA, C09CA            |
| Exposure to immunosuppressants  | ATC L04                     |

Abbreviations: ACE-inhibitor – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; ATC – anatomical therapeutic classification, BNF – British National Formulary, ICD – international classification of diseases. *For chronic respiratory disease, the presence of a single ICD-10 code in SMR01 data OR a single BNF code in community prescription data was necessary and sufficient to assess the presence of the comorbidity.*
Supplementary Tables
### Supplementary Table 1. Clinical characteristics of patients included in Cohorts 1 and 2.

|                          | COHORT 1          | COHORT 2          |
|--------------------------|-------------------|-------------------|
| **Number of patients, n** | **36,904**        | **50,060**        |
| **Age, years**           | **61 (21)**       | **63 (20)**       |
| **Sex**                  |                   |                   |
| Women                    | **21,458 (58.1)** | **31,028 (62.0)** |
| Men                      | **15,446 (41.9)** | **19,032 (38.0)** |
| **SIMD quintile**        |                   |                   |
| 1 (most deprived)        | **5,458 (14.8)**  | **9,675 (19.3)**  |
| 2                        | **9,154 (24.8)**  | **9,587 (19.2)**  |
| 3                        | **6,510 (17.6)**  | **9,525 (19.0)**  |
| 4                        | **6,393 (17.3)**  | **13,030 (26.0)** |
| 5 (least deprived)       | **9,145 (24.8)**  | **8,242 (16.5)**  |
| **Co-existing medical conditions** |               |                   |
| Angina                   | **1,917 (5.2)**   | **1,660 (3.3)**   |
| Atrial fibillation*      | -                 | **3,869 (7.7)**   |
| Myocardial infarction    | **2,874 (7.8)**   | **2,170 (4.3)**   |
| Heart failure            | **2,751 (7.5)**   | **1,804 (3.6)**   |
| Stroke                   | **2,817 (7.6)**   | **2,485 (5.0)**   |
| Diabetes                 | **6,177 (16.7)**  | **9,085 (18.1)**  |
| Cancer                   | **7,288 (19.7)**  | **3,525 (7.0)**   |
| Chronic lower respiratory disease | **9,861 (26.7)** | **10,540 (21.1)** |
| Chronic liver disease    | **1,301 (3.5)**   | **822 (1.6)**     |
| **Renal history**        |                   |                   |
| CKD                      | **5,853 (15.9)**  | **8,201 (16.4)**  |
| End-stage kidney disease | **337 (0.9)**     | **240 (0.5)**     |
| Baseline eGFR            | **83 (25)**       | **86 (26)**       |
| Baseline eGFR category   |                   |                   |
| ≥90                      | **15,486 (42.0)** | **22,784 (45.5)** |
| 60 – 89                  | **15,565 (42.2)** | **19,075 (38.1)** |
| 45 – 59                  | **2,708 (7.3)**   | **4,264 (8.5)**   |
| 30 – 44                  | **1,868 (5.1)**   | **2,549 (5.1)**   |
| 15 – 29                  | **787 (2.1)**     | **914 (1.8)**     |
| ≤15                      | **490 (1.3)**     | **474 (0.9)**     |
| **Current medication**   |                   |                   |
| ACE-inhibitor or ARB     | **9,022 (24.4)**  | **10,673 (21.3)** |
| Aspirin*                 | -                 | **5,492 (11.0)**  |
| Other antiplatelet agent*| -                 | **3,335 (6.7)**   |
| Beta-blockers*           | -                 | **9,314 (18.6)**  |
| Immunosuppressants       | **860 (2.3)**     | **421 (0.8)**     |
| Loop diuretic*           | -                 | **5,432 (10.9)**  |
| Mineralocorticoid receptor antagonist* | - | **1,332 (2.7)** |
| Novel oral anticoagulant*| -                 | **3,450 (6.9)**   |
| Warfarin*                | -                 | **1,238 (2.5)**   |

Values are mean ± SD, n (%), or median (interquartile range). Abbreviations: ACE-inhibitor – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate (ml/min/1.73 m²); SIMD – Scottish index of multiple deprivation. *data not available for Cohort 1.
**Supplementary Table 2.** Clinical characteristics of patients included in Cohorts 1 and 2, grouped by COVID-19 status.

|                          | COHORT 1                  | COHORT 2                  |
|--------------------------|---------------------------|---------------------------|
|                          | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
| Number of patients, n    | 3,731                  | 33,173                  | 4,556                  | 45,504              |
| Age, years               | 63 (22)                 | 61 (20)                  | 64 (21)                 | 63 (20)              |
| Sex                      |                          |                          |                          |                      |
| Women                    | 2,110 (56.6)            | 19,348 (58.3)            | 2,955 (64.9)            | 28,073 (61.7)        |
| Men                      | 1,621 (43.4)            | 13,825 (41.7)            | 1,601 (35.1)            | 17,431 (38.3)        |
| SIMD quintile            |                          |                          |                          |                      |
| 1 (most deprived)        | 579 (15.5)              | 4,879 (14.7)             | 993 (21.8)              | 8,682 (19.1)         |
| 2                        | 1,002 (26.9)            | 8,152 (24.6)             | 932 (20.5)              | 8,655 (19.0)         |
| 3                        | 645 (17.3)              | 5,865 (17.7)             | 847 (18.6)              | 8,678 (19.1)         |
| 4                        | 631 (16.9)              | 5,762 (17.4)             | 1,121 (24.6)            | 11,909 (26.2)        |
| 5 (least deprived)       | 858 (23.0)              | 8,287 (25.0)             | 663 (14.6)              | 7,579 (16.7)         |
| Co-existing medical conditions |                      |                          |                          |                      |
| Angina                   | 216 (5.8)               | 1,701 (5.1)              | 167 (3.7)               | 1,493 (3.3)          |
| Atrial fibrillation*     |                          |                          | 422 (9.3)               | 3,447 (7.6)          |
| Myocardial infarction    | 302 (8.1)               | 2,572 (7.8)              | 187 (4.1)               | 1,983 (4.4)          |
| Heart failure            | 331 (8.9)               | 2,420 (7.3)              | 217 (4.8)               | 1,587 (3.5)          |
| Stroke                   | 384 (10.3)              | 2,433 (7.3)              | 360 (7.9)               | 2,125 (4.7)          |
| Diabetes                 | 766 (20.5)              | 5,411 (16.3)             | 866 (19.0)              | 8,219 (18.1)         |
| Cancer                   | 543 (14.6)              | 6,745 (20.3)             | 252 (5.5)               | 3,273 (7.2)          |
| Chronic lower respiratory disease | 1,032 (27.7) | 8,829 (26.6)             | 866 (19.0)              | 9,674 (21.3)         |
| Chronic liver disease    | 104 (2.8)               | 1,197 (3.6)              | 61 (1.3)                | 761 (1.7)            |
| Renal history            |                          |                          |                          |                      |
| CKD                      | 734 (19.7)              | 5,119 (15.4)             | 865 (19.0)              | 7,336 (16.1)         |
| End-stage kidney disease | 35 (0.9)                | 302 (0.8)                | 29 (0.6)                | 211 (0.5)            |
| Baseline eGFR            | 80 (27)                 | 84 (25)                  | 84 (26)                 | 86 (26)              |
| Baseline eGFR category   |                          |                          |                          |                      |
| ≥90                      | 1,396 (37.4)            | 14,090 (42.5)            | 2,020 (44.3)            | 20,764 (45.6)        |
| 60 – 89                  | 1,601 (42.9)            | 13,964 (42.1)            | 1,671 (36.7)            | 17,404 (38.2)        |
| 45 – 59                  | 314 (8.4)               | 2,394 (7.2)              | 436 (9.6)               | 3,828 (8.4)          |
| 30 – 44                  | 236 (6.3)               | 1,632 (4.9)              | 270 (5.9)               | 2,279 (5.0)          |
| 15 – 29                  | 118 (3.2)               | 669 (2.0)                | 105 (2.3)               | 809 (1.8)            |
| ≤15                      | 66 (1.8)                | 424 (1.3)                | 54 (1.2)                | 420 (0.9)            |
| Current medication       |                          |                          |                          |                      |
| ACE-inhibitor or ARB     | 937 (25.1)              | 8,085 (24.4)             | 807 (17.7)              | 9,866 (21.7)         |
| Aspirin*                 | -                       | -                        | 456 (10.0)              | 5,036 (11.1)         |
| Other antiplatelet agent*| -                       | -                        | 375 (8.2)               | 2,960 (6.5)          |
| Beta-blockers*           | -                       | -                        | 797 (17.5)              | 8,517 (18.7)         |
| Immunosuppressants       | 93 (2.5)                | 767 (2.3)                | 24 (0.5)                | 397 (0.9)            |
| Loop diuretic*           | -                       | -                        | 567 (12.4)              | 4,865 (10.7)         |
| Mineralocorticoid receptor antagonist* | -                     | -                        | 130 (2.9)               | 1,202 (2.6)          |
| Novel oral anticoagulant*| -                       | -                        | 296 (6.5)               | 3,154 (6.9)          |
| Warfarin*                | -                       | -                        | 88 (1.9)                | 1,150 (2.5)          |

Values are mean ± SD, n (%), or median (interquartile range). Abbreviations: ACE-inhibitor – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate (ml/min/1.73 m²); SIMD – Scottish index of multiple deprivation. *data not available for Cohort 1.
### Supplementary Table 3. Clinical characteristics of patients included in Cohorts 1 and 2, grouped by CKD status.

|                        | COHORT 1 | COHORT 2 | COHORT 1 | COHORT 2 |
|------------------------|----------|----------|----------|----------|
| **COHORT 1**           |          |          |          |          |
| **COHORT 2**           |          |          |          |          |
| Number of patients, n  | CKD 5,853| No CKD 31,051| CKD 8,201| No CKD 41,859|
| Age, years             | 79 (12)  | 58 (20)  | 82 (10)  | 59 (19)  |
| Sex                    |          |          |          |          |
| Women                  | 3,148 (53.8) | 18,310 (59.0) | 4,879 (59.5) | 26,149 (62.5) |
| Men                    | 2,705 (46.2) | 12,741 (41.0) | 3,322 (40.5) | 15,710 (37.5) |
| SIMD quintile          |          |          |          |          |
| 1 (most deprived)      | 719 (12.3) | 4,739 (15.3) | 1,322 (16.1) | 3,853 (20.0) |
| 2                      | 1,487 (25.4) | 7,667 (24.7) | 1,576 (19.2) | 8,011 (19.1) |
| 3                      | 1,033 (17.6) | 5,477 (17.6) | 1,673 (20.4) | 7,852 (18.8) |
| 4                      | 1,001 (17.1) | 5,392 (17.4) | 2,193 (26.7) | 10,837 (25.9) |
| 5 (least deprived)    | 1,602 (27.4) | 7,558 (24.3) | 1,437 (17.5) | 6,805 (16.3) |
| Co-existing medical conditions |          |          |          |          |
| Angina                 | 662 (11.3) | 1,255 (4.0) | 602 (7.3) | 1,058 (2.5) |
| Atrial fibrillation*   | -        | -        | 1,651 (20.1) | 2,218 (5.3) |
| Myocardial infarction  | 931 (15.9) | 1,943 (6.3) | 835 (10.2) | 1,335 (3.2) |
| Heart failure          | 1,348 (23.0) | 1,403 (4.5) | 980 (11.9) | 824 (2.0) |
| Stroke                 | 831 (14.2) | 1,986 (6.4) | 794 (9.7) | 1,691 (4.0) |
| Diabetes               | 2,094 (35.8) | 4,083 (13.1) | 2,665 (32.5) | 6,420 (15.3) |
| Cancer                 | 1,531 (26.2) | 5,757 (18.5) | 956 (11.7) | 2,569 (6.1) |
| Chronic lower respiratory disease | 1,641 (28.0) | 8,220 (26.5) | 2,109 (25.7) | 8,431 (20.1) |
| Chronic liver disease  | 240 (4.1) | 1,061 (3.4) | 192 (2.3) | 630 (1.5) |
| Renal history          |          |          |          |          |
| End-stage kidney disease | 337 (5.8) | - | 240 (2.9) | - |
| Baseline eGFR          | 42 (14)  | 91 (18)  | 44 (12)  | 94 (19)  |
| Baseline eGFR category |          |          |          |          |
| ≥90                    | -        | 15,486 (49.9) | - | 22,784 (54.4) |
| 60 – 89                | -        | 15,565 (60.1) | - | 19,075 (45.6) |
| 45 – 59                | 2,708 (46.3) | - | 4,264 (52.0) | - |
| 30 – 44                | 1,868 (31.9) | - | 2,549 (31.1) | - |
| 15 – 29                | 787 (13.4) | - | 914 (11.1) | - |
| ≤15                    | 490 (8.4) | - | 474 (5.8) | - |
| Current medication     |          |          |          |          |
| ACE-inhibitor or ARB   | 2,389 (40.8) | 6,633 (21.4) | 2,913 (35.5) | 7,760 (18.5) |
| Aspirin*               | -        | -        | 1,756 (21.4) | 3,736 (8.9) |
| Other antiplatelet agent* | -        | -        | 989 (12.1) | 2,346 (5.6) |
| Beta-blockers*         | -        | -        | 2,955 (36.0) | 6,359 (15.2) |
| Immunosuppressants     | 228 (3.9) | 632 (2.0) | 162 (2.0) | 259 (0.6) |
| Loop diuretic*         | -        | -        | 2,615 (31.9) | 2,817 (6.7) |
| Mineralocorticoid receptor antagonist* | -        | -        | 624 (7.6) | 708 (1.7) |
| Novel oral anticoagulant* | -        | -        | 1,278 (15.6) | 2,172 (5.2) |
| Warfarin               | -        | -        | 542 (6.6) | 696 (1.7) |

Values are mean ± SD, n (%), or median (interquartile range). Abbreviations: ACE-inhibitor – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate (ml/min/1.73 m²); SIMD – Scottish index of multiple deprivation. *data not available for Cohort 1.
## Supplementary Table 4. Clinical characteristics of patients included in Cohorts 1 and 2, grouped according to COVID-19 and CKD status.

|                      | **COHORT 1** | **COHORT 2** |
|----------------------|--------------|--------------|
|                      | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
| Number of patients, n| 734 (29.7)    | 2,997 (35.8)  | 865 (17.6)       | 3,691 (22.5)      |
| Age, years           | 61 (15.3)     | 51 (15.4)     | 124 (15.4)       | 178 (18.0)        |
| Sex                  | 398 (52.3)    | 1,726 (57.6)  | 508 (58.0)       | 2,453 (66.5)      |
| SIMD quintile        | 103 (14.0)    | 476 (15.9)    | 616 (12.0)       | 4,263 (15.2)      |
| Co-existing medical conditions | 91 (12.4) | 125 (4.2) | 571 (11.2) | 1,130 (4.0) |
| Angina               | -             | -             | 69 (8.0)         | 98 (2.7)          |
| Atrial fibrillation* | -             | -             | 207 (23.9)       | 215 (5.8)         |
| Myocardial infarction| 124 (16.9)    | 178 (5.9)     | 807 (15.8)       | 1,765 (6.3)       |
| Heart failure        | 196 (26.7)    | 135 (4.5)     | 1,152 (22.5)     | 1,268 (4.5)       |
| Stroke               | 127 (17.3)    | 257 (8.6)     | 704 (13.8)       | 1,729 (6.2)       |
| Diabetes             | 275 (37.5)    | 491 (16.4)    | 1,819 (35.5)     | 3,592 (12.8)      |
| Cancer               | 159 (21.7)    | 384 (12.8)    | 1,372 (26.8)     | 5,373 (19.2)      |
| Chronic lower respiratory disease | 223 (30.4) | 809 (27.0) | 1,418 (27.7) | 7,411 (26.4) |
| Chronic liver disease| 27 (3.7)      | 77 (2.6)      | 213 (4.2)        | 984 (3.5)         |
| Renal history        | -             | -             | 21 (2.4)         | 40 (1.1)          |
| End-stage kidney disease | 35 (4.8) | -             | 29 (3.4)         | 211 (2.9)        |
| Baseline eGFR category | 40 (14)       | 90 (19)       | 42 (14)         | 91 (18)          |
| Baseline eGFR ≥90    | -             | 1,396 (46.6)  | 14,090 (50.2)    | 2,020 (54.7)      |
| 60 – 89              | -             | 1,601 (53.4)  | 13,964 (49.8)    | 1,671 (45.3)      |
| 45 – 59              | 314 (42.8)    | 2,394 (46.8)  | 436 (50.4)       | 3,828 (52.2)      |
| 30 – 44              | 236 (32.2)    | 1,632 (31.9)  | 270 (31.2)       | 2,279 (31.1)      |
| 15 – 29              | 118 (16.1)    | 669 (13.1)    | 105 (12.1)       | 809 (11.0)        |
| ≤15                  | 66 (9.0)      | 424 (8.3)     | 54 (6.2)         | 420 (5.7)         |
| Current medication   | -             | -             | 218 (25.2)       | 589 (16.0)        |
| ACE-inhibitor or ARB | 263 (35.8)    | 674 (22.5)    | 5,959 (21.2)     | 2,655 (36.2)      |
| Aspirin*             | -             | -             | 157 (18.1)       | 299 (8.1)         |
| Other antiplatelet agent* | -         | -             | 128 (14.8)       | 247 (6.7)         |
| Beta-blockers*       | -             | -             | 300 (34.7)       | 497 (13.5)        |
| Category                                | Cohort 1 | Cohort 2 | Cohort 3 | Cohort 4 | Cohort 5 | Cohort 6 |
|-----------------------------------------|----------|----------|----------|----------|----------|----------|
| Immunosuppressants                      | 27 (3.7) | 66 (2.2) | 201 (3.9)| 566 (2.0)| 11 (1.3) | 13 (0.4) |
| Loop diuretic*                          | -        | -        | -        | -        | 303 (35.0)| 264 (7.1)|
| Mineralocorticoid receptor antagonist*  | -        | -        | -        | -        | 66 (7.6)  | 64 (1.7)  |
| Novel oral anticoagulant*               | -        | -        | -        | -        | 142 (16.4)| 154 (4.2)|
| Warfarin*                               | -        | -        | -        | -        | 43 (5.0)  | 45 (1.2)  |
| Loop diuretic*                          | -        | -        | -        | -        | 2,312 (31.5)| 2,553 (6.7)|
| Mineralocorticoid receptor antagonist*  | -        | -        | -        | -        | 558 (7.6) | 644 (1.7) |
| Novel oral anticoagulant*               | -        | -        | -        | -        | 1,136 (15.5)| 2,018 (5.3)|
| Warfarin*                               | -        | -        | -        | -        | 499 (6.8) | 651 (1.7) |

Values are mean ± SD, n (%), or median (interquartile range). Abbreviations: ACE-inhibitor – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate (ml/min/1.73 m²); SIMD – Scottish index of multiple deprivation.

*data not available for Cohort 1.
Supplementary Table 5. Summary of unadjusted hazard ratios and 95% confidence intervals relating to cardiovascular, all-cause, and COVID-19-related death for primary (A) and secondary (B) analyses.

|                      | COHORT 1 |                      | COHORT 2 |                      |
|----------------------|----------|----------------------|----------|----------------------|
|                      | Unadjusted Hazard Ratio | Lower 95% CI | Upper 95% CI | Unadjusted Hazard Ratio | Lower 95% CI | Upper 95% CI |
| **A) COVID-19 positive versus negative** |          |                      |          |                      |
| **CKD**              |          |                      |          |                      |
| Cardiovascular death*|          |                      |          |                      |
| 30 days              | 2.65     | 1.97                 | 3.58     | 2.42                 | 1.83        | 3.20        |
| 90 days              | 2.15     | 1.66                 | 2.78     | 1.69                 | 1.31        | 2.16        |
| End of study follow-up | 1.99   | 1.58                 | 2.51     | 1.50                 | 1.21        | 1.87        |
| All-cause death      |          |                      |          |                      |
| 30 days              | 4.81     | 4.13                 | 5.61     | 4.71                 | 4.10        | 5.40        |
| 90 days              | 3.33     | 2.92                 | 3.80     | 3.14                 | 2.78        | 3.54        |
| End of study follow-up | 2.79  | 2.48                 | 3.15     | 2.51                 | 2.25        | 2.80        |
| **No CKD**           |          |                      |          |                      |
| Cardiovascular death*|          |                      |          |                      |
| 30 days              | 2.20     | 1.65                 | 2.94     | 1.86                 | 1.40        | 2.48        |
| 90 days              | 1.81     | 1.40                 | 2.34     | 1.48                 | 1.16        | 1.91        |
| End of study follow-up | 1.76   | 1.40                 | 2.21     | 1.24                 | 1.00        | 1.53        |
| All-cause death      |          |                      |          |                      |
| 30 days              | 4.05     | 3.60                 | 4.55     | 4.26                 | 3.80        | 4.78        |
| 90 days              | 2.81     | 2.54                 | 3.11     | 2.87                 | 2.59        | 3.18        |
| End of study follow-up | 2.25  | 2.05                 | 2.46     | 2.03                 | 1.85        | 2.22        |
| **B) CKD versus no CKD** |        |                      |          |                      |
| **COVID-19 positive** |         |                      |          |                      |
| Cardiovascular death*|          |                      |          |                      |
| 30 days              | 4.53     | 3.14                 | 6.54     | 5.62                 | 3.91        | 8.08        |
| 90 days              | 4.97     | 3.56                 | 6.92     | 5.29                 | 3.81        | 7.36        |
| End of study follow-up | 4.80  | 3.56                 | 6.47     | 5.60                 | 4.19        | 7.47        |
| All-cause death      |          |                      |          |                      |
| 30 days              | 3.03     | 2.59                 | 3.54     | 3.70                 | 3.19        | 4.30        |
| 90 days              | 3.06     | 2.65                 | 3.53     | 3.73                 | 3.24        | 4.29        |
| End of study follow-up | 3.09  | 2.70                 | 3.53     | 3.95                 | 3.47        | 4.50        |
| COVID-19-related death* |        |                      |          |                      |
| 30 days              | 3.07     | 2.62                 | 3.61     | 3.67                 | 3.16        | 4.27        |
| 90 days              | 3.10     | 2.65                 | 3.61     | 3.69                 | 3.19        | 4.27        |
| End of study follow-up | 3.11  | 2.67                 | 3.63     | 3.75                 | 3.24        | 4.33        |
| **COVID-19 negative** |         |                      |          |                      |
| Cardiovascular death*|          |                      |          |                      |
| 30 days              | 3.81     | 3.14                 | 4.62     | 4.30                 | 3.64        | 5.07        |
|                           | 90 days |   |   |   |
|---------------------------|---------|---|---|---|
| All-cause death           | 4.36    | 3.74| 5.08|   |
| End of study follow-up    | 4.39    | 3.87| 4.99|   |
|                           | 4.83    | 4.26| 5.48|   |
|                           | 4.95    | 4.49| 5.47|   |
|                           | 4.26    | 3.71| 3.85|   |
|                           | 3.04    | 3.32| 3.85|   |
|                           | 3.71    | 3.37| 3.78|   |

**Abbreviations:** CKD – chronic kidney disease; CI – confidence interval. *Hazard ratios for cardiovascular and COVID-19-related death are cause-specific.*
**Supplementary Table 6.** Outcomes of patients included in sensitivity analysis, in which study cohorts were restricted to patients not hospitalised either in the week before or in the two weeks following their index COVID-19 test. Patients are grouped according to COVID-19 and CKD status.

|                     | COHORT 1 |                      | COHORT 2 |                      |
|---------------------|----------|----------------------|----------|----------------------|
|                     | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
| Number of patients, n | CKD 314 | No CKD 574 | CKD 1,786 | No CKD 9,575 | CKD 460 | No CKD 1,877 | CKD 2,717 | No CKD 18,526 |
| Primary outcomes    |          |                      |          |                      |
| Cardiovascular death|          |                      |          |                      |
| 30 days             | 18 (5.7) | 6 (1.0)              | 22 (1.2) | 12 (0.1)             | 21 (4.6) | 35 (1.9) | 20 (0.7) | 46 (0.2) |
| 90 days             | 23 (7.3) | 17 (3.0)             | 28 (1.6) | 27 (0.3)             | 25 (5.4) | 67 (3.6) | 27 (1.0) | 90 (0.5) |
| End of study follow-up | 29 (9.2) | 41 (7.1)             | 37 (2.1) | 57 (0.6)             | 37 (8.0) | 131 (7.0) | 44 (1.6) | 181 (1.0) |
| All-cause death     |          |                      |          |                      |
| 30 days             | 99 (31.5)| 29 (5.1)             | 144 (8.1)| 112 (1.2)            | 141 (30.6)| 95 (5.1) | 193 (7.1)| 156 (0.8) |
| 90 days             | 120 (38.2)| 61 (10.6)           | 182 (10.2)| 208 (2.2)            | 161 (35.0)| 200 (10.6)| 220 (8.1)| 306 (1.6) |
| End of study follow-up | 138 (43.9)| 125 (21.8) | 215 (12.0)| 371 (3.9)            | 192 (41.7)| 401 (21.4)| 274 (10.1)| 673 (3.6) |
Supplementary Table 7. Summary of adjusted hazard ratios and 95% confidence intervals from sensitivity analysis, in which study cohorts were restricted to patients not hospitalised either in the week before or in the two weeks following their index COVID-19 test.

| COVID-19 positive versus negative | COHORT 1 | COHORT 2 |
|----------------------------------|----------|----------|
|                                  | Adjusted Hazard Ratio | Lower 95% CI | Upper 95% CI | Adjusted Hazard Ratio | Lower 95% CI | Upper 95% CI |
| CKD                              |           |           |            |                   |           |           |
| Cardiovascular death*            |           |           |            |                   |           |           |
| 30 days                          | 6.70      | 2.19      | 20.51      | 2.30              | 1.10      | 4.81      |
| 90 days                          | 2.62      | 1.26      | 5.45       | 1.46              | 0.81      | 2.62      |
| End of study follow-up           | 2.02      | 1.17      | 3.47       | 1.37              | 0.87      | 2.16      |
| All-cause death                  |           |           |            |                   |           |           |
| 30 days                          | 7.48      | 4.69      | 11.93      | 5.93              | 3.97      | 8.84      |
| 90 days                          | 4.04      | 2.87      | 5.69       | 3.37              | 2.50      | 4.53      |
| End of study follow-up           | 2.63      | 2.03      | 3.41       | 2.36              | 1.87      | 2.98      |
| No CKD                           |           |           |            |                   |           |           |
| Cardiovascular death*            |           |           |            |                   |           |           |
| 30 days                          | 3.43      | 1.55      | 7.58       | 2.30              | 1.06      | 5.00      |
| 90 days                          | 2.35      | 1.32      | 4.16       | 1.50              | 0.84      | 2.69      |
| End of study follow-up           | 1.66      | 1.09      | 2.54       | 1.35              | 0.87      | 2.09      |
| All-cause death                  |           |           |            |                   |           |           |
| 30 days                          | 3.93      | 2.94      | 5.25       | 6.69              | 4.58      | 9.77      |
| 90 days                          | 2.68      | 2.14      | 3.35       | 3.91              | 2.95      | 5.18      |
| End of study follow-up           | 1.82      | 1.52      | 2.19       | 2.41              | 1.96      | 2.97      |

Abbreviations: CKD – chronic kidney disease; CI – confidence interval. *Hazard ratios for cardiovascular death are cause-specific.
Supplementary Table 8. Outcomes of patients included in Cohorts 1 and 2, grouped according to COVID-19 and CKD status.

| COHORT 1 | COHORT 2 |
|-----------|-----------|
|           | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
|           | CKD | No CKD | CKD | No CKD | CKD | No CKD | CKD | No CKD |
| Number of patients, n | 734 | 2,997 | 5,119 | 28,054 | 865 | 3,691 | 7,336 | 38,168 |

**Primary outcomes**

|                      |          |          |          |          |          |          |          |          |
|----------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                      | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
|                      | CKD | No CKD | CKD | No CKD | CKD | No CKD | CKD | No CKD |
| Cardiovascular death |      |        |      |        |      |        |      |        |
| 30 days              | 57 (7.8) | 57 (1.9) | 172 (3.4) | 254 (0.9) | 62 (7.2) | 55 (1.5) | 254 (3.5) | 316 (0.8) |
| 90 days              | 72 (9.8) | 68 (2.3) | 290 (5.7) | 377 (1.3) | 72 (8.3) | 70 (1.9) | 453 (6.2) | 515 (1.3) |
| End of follow-up     | 86 (11.7) | 86 (2.9) | 426 (8.3) | 542 (1.9) | 92 (10.6) | 94 (2.5) | 730 (10.0) | 840 (2.2) |
| COVID-19-related death |     |        |      |        |      |        |      |        |
| 30 days              | 250 (34.1) | 377 (12.6) | - | - | 295 (34.1) | 397 (10.8) | - | - |
| 90 days              | 267 (36.4) | 404 (13.5) | - | - | 313 (36.2) | 423 (11.5) | - | - |
| End of follow-up     | 270 (36.8) | 407 (13.6) | - | - | 318 (36.8) | 427 (11.6) | - | - |
| All-cause death      |        |        |      |        |      |        |      |        |
| 30 days              | 260 (35.4) | 399 (13.3) | 442 (8.6) | 974 (3.5) | 302 (34.9) | 405 (11.0) | 642 (8.8) | 1,025 (2.7) |
| 90 days              | 304 (41.4) | 473 (15.8) | 803 (15.7) | 1,702 (6.1) | 342 (39.5) | 466 (12.6) | 1,157 (15.8) | 1,782 (4.7) |
| End of follow-up     | 346 (47.1) | 541 (18.1) | 1,246 (24.3) | 2,688 (9.6) | 397 (45.9) | 547 (14.8) | 1,880 (25.6) | 3,007 (7.9) |

**Secondary outcomes**

|                      |          |          |          |          |          |          |          |          |
|----------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|                      | COVID-19 positive | COVID-19 negative | COVID-19 positive | COVID-19 negative |
|                      | CKD | No CKD | CKD | No CKD | CKD | No CKD | CKD | No CKD |
| Fatal/non-fatal myocardial infarction |      |        |      |        |      |        |      |        |
| 30 days              | 7 (1.0) | 8 (0.3) | 132 (2.6) | 254 (0.9) | 9 (1.0) | NA | 154 (2.1) | 386 (1.0) |
| 90 days              | 8 (1.1) | 9 (0.3) | 155 (3.0) | 293 (1.0) | 9 (1.0) | 9 (0.2) | 193 (2.6) | 428 (1.1) |
| End of follow-up     | 11 (1.5) | 15 (0.5) | 190 (3.7) | 351 (1.3) | 13 (1.5) | 11 (0.3) | 248 (3.4) | 505 (1.3) |
| Fatal myocardial infarction |      |        |      |        |      |        |      |        |
| End of follow-up NA  | NA | 62 (1.2) | 74 (0.3) | 7 (0.8) | 10 (0.3) | 113 (1.5) | 142 (0.4) |
| Fatal/non-fatal heart failure |      |        |      |        |      |        |      |        |
| 30 days              | 16 (2.2) | NA | 117 (2.3) | 133 (0.5) | 21 (2.4) | 6 (0.2) | 348 (4.7) | 362 (0.9) |
| 90 days              | 21 (2.9) | 8 (0.3) | 168 (3.3) | 166 (0.6) | 23 (2.7) | 8 (0.2) | 423 (5.8) | 414 (1.1) |
| End of follow-up     | 24 (3.3) | 10 (0.3) | 226 (4.4) | 212 (0.8) | 28 (3.2) | 14 (0.4) | 496 (6.8) | 478 (1.3) |
| Fatal heart failure  |      |        |      |        |      |        |      |        |
| End of follow-up     | 18 (2.5) | NA | 88 (1.7) | 60 (0.2) | 20 (2.3) | 11 (0.3) | 182 (2.5) | 93 (0.2) |
| Fatal/non-fatal stroke |      |        |      |        |      |        |      |        |
|                        | 30 days  | 90 days  | End of follow-up |
|------------------------|----------|----------|------------------|
| **Fatal stroke**       | 10 (1.4) | 13 (1.8) | 16 (2.2)         |
| **Fatal/non-fatal pulmonary embolism** | 18 (0.6) | 23 (0.8) | 28 (0.9)         |
| **Fatal pulmonary embolism** | 96 (1.9) | 121 (2.4) | 158 (3.1)       |
| **Atrial fibrillation hospitalisations** | 348 (1.2) | 415 (1.5) | 487 (1.7)        |
| **Cardiovascular hospitalisations** | 15 (1.7) | 19 (2.2) | 25 (2.9)         |
| **All hospitalisations** | 31 (0.8) | 38 (1.0) | 44 (1.2)         |
|                        | 249 (3.4) | 294 (4.0) | 348 (4.7)        |
|                        | 574 (1.5) | 648 (1.7) | 744 (1.9)        |
| **End of follow-up**   | 6 (0.8)  | 15 (1.7) | 31 (0.8)         |
| **Fatal stroke**       | 13 (1.8) | 19 (2.2) | 25 (2.9)         |
| **Fatal/non-fatal pulmonary embolism** | 23 (0.8) | 38 (1.0) | 44 (1.2)         |
| **Fatal pulmonary embolism** | 57 (1.1) | 135 (0.5) | 263 (3.6) |
| **Atrial fibrillation hospitalisations** | 11 (0.2) | 20 (0.1) | 11 (0.1)         |
| **Cardiovascular hospitalisations** | 28 (3.8) | 41 (5.6) | 54 (7.4)         |
| **All hospitalisations** | 7 (0.2)  | 12 (1.6) | 15 (2.0)         |
| **Cardiovascular hospitalisations** | 189 (3.7) | 225 (4.4) | 292 (5.7)       |
| **All hospitalisations** | 461 (1.6) | 557 (2.0) | 676 (2.4)       |
| **Cardiovascular hospitalisations** | 7 (0.8)  | 12 (1.4) | 24 (2.8)         |
| **All hospitalisations** | 10 (0.3) | 13 (0.3) | 24 (0.6)         |
|                        | 259 (3.5) | 303 (4.1) | 435 (5.9)       |
|                        | 626 (1.6) | 714 (1.9) | 939 (2.5)       |
| **Fatal stroke**       | 12 (1.6) | 15 (1.7) | 31 (0.8)         |
| **Fatal/non-fatal pulmonary embolism** | 18 (0.6) | 23 (0.8) | 28 (0.9)         |
| **Fatal pulmonary embolism** | 96 (1.9) | 121 (2.4) | 158 (3.1)       |
| **Atrial fibrillation hospitalisations** | 348 (1.2) | 415 (1.5) | 487 (1.7)        |
| **Cardiovascular hospitalisations** | 15 (1.7) | 19 (2.2) | 25 (2.9)         |
| **All hospitalisations** | 31 (0.8) | 38 (1.0) | 44 (1.2)         |
| **Cardiovascular hospitalisations** | 249 (3.4) | 294 (4.0) | 348 (4.7)       |
| **All hospitalisations** | 574 (1.5) | 648 (1.7) | 744 (1.9)       |
| **Fatal stroke**       | 6 (0.8)  | 15 (1.7) | 31 (0.8)         |
| **Fatal/non-fatal pulmonary embolism** | 14 (0.5) | 19 (2.2) | 31 (0.8)         |
| **Fatal pulmonary embolism** | 57 (1.1) | 135 (0.5) | 263 (3.6) |
| **Atrial fibrillation hospitalisations** | 11 (0.2) | 20 (0.1) | 11 (0.1)         |
| **Cardiovascular hospitalisations** | 28 (3.8) | 41 (5.6) | 54 (7.4)         |
| **All hospitalisations** | 7 (0.2)  | 12 (1.6) | 15 (2.0)         |
| **Cardiovascular hospitalisations** | 189 (3.7) | 225 (4.4) | 292 (5.7)       |
| **All hospitalisations** | 461 (1.6) | 557 (2.0) | 676 (2.4)       |
| **Cardiovascular hospitalisations** | 7 (0.8)  | 12 (1.4) | 24 (2.8)         |
| **All hospitalisations** | 10 (0.3) | 13 (0.3) | 24 (0.6)         |
| **Cardiovascular hospitalisations** | 259 (3.5) | 303 (4.1) | 435 (5.9)       |
| **All hospitalisations** | 626 (1.6) | 714 (1.9) | 939 (2.5)       |
| **Fatal stroke**       | NA       | 15 (0.5) | 60 (1.2)         |
| **Fatal/non-fatal pulmonary embolism** | NA       | 15 (0.5) | 60 (1.2)         |
| **Fatal pulmonary embolism** | 189 (3.7) | 225 (4.4) | 292 (5.7) |
| **Atrial fibrillation hospitalisations** | 28 (3.8) | 41 (5.6) | 54 (7.4)         |
| **Cardiovascular hospitalisations** | NA       | 15 (0.5) | 60 (1.2)         |
| **All hospitalisations** | 57 (1.1) | 135 (0.5) | 263 (3.6) |
| **Fatal stroke**       | NA       | NA       | 11 (0.2)         |
| **Fatal/non-fatal pulmonary embolism** | NA       | NA       | 11 (0.2)         |
| **Fatal pulmonary embolism** | 189 (3.7) | 225 (4.4) | 292 (5.7) |
| **Atrial fibrillation hospitalisations** | NA       | NA       | 11 (0.2)         |
| **Cardiovascular hospitalisations** | 28 (3.8) | 41 (5.6) | 54 (7.4)         |
| **All hospitalisations** | 7 (0.2)  | 12 (1.6) | 15 (2.0)         |
| **Cardiovascular hospitalisations** | 189 (3.7) | 225 (4.4) | 292 (5.7)       |
| **All hospitalisations** | 461 (1.6) | 557 (2.0) | 676 (2.4)       |
| **Cardiovascular hospitalisations** | 7 (0.8)  | 12 (1.4) | 24 (2.8)         |
| **All hospitalisations** | 10 (0.3) | 13 (0.3) | 24 (0.6)         |
| **Cardiovascular hospitalisations** | 259 (3.5) | 303 (4.1) | 435 (5.9)       |
| **All hospitalisations** | 626 (1.6) | 714 (1.9) | 939 (2.5)       |
Supplementary Figures
**Supplementary Figure 1.** Flow diagrams for Cohorts 1 (a) and 2 (b). Abbreviations: AKI – acute kidney injury; CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate (ml/min/1.73 m²); KTx – kidney transplant; HD – haemodialysis; PD – peritoneal dialysis; RRT – renal replacement therapy.

a) Cohort 1

*See Methods for definitions. Abbreviations: AKI – acute kidney injury CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate; KTx – kidney transplant; HD – haemodialysis; PD – peritoneal dialysis; RRT – renal replacement therapy;
b) Cohort 2

Patients with at least one COVID-19 test* between 02/28/2020 and 02/08/2021:
N = 51,505

EXCLUDED
- < 18 years old at time of index* COVID-19 test: N = 588
- < 1 year of full records: N = 91
- No renal function recorded prior to index COVID-19 test: N = 5
- Left NHS Tayside/Fife before study end: N = 164
- Died before index date: N = 18

Assessed for CKD e-phenotype*:
N = 50,399

CKD e-phenotype present
N = 7,961

CKD e-phenotype absent
(i.e. No CKD)
N = 42,438

Most proximal eGFR < 60 mL/min/1.73m²
N = 579
Reasons: AKI, new CKD onset or only one eGFR measurement < 60 mL/min/1.73m² in 2 years prior to index COVID-19 test

CKD group: N = 8,201
(7,961 + 240 on RRT)
G3a: N = 4,264
G3b: N = 2,549
G4: N = 914
G5: N = 234

Normal eGFR group: N = 41,859
G1: N = 22,784
G2: N = 19,075

Total patients included in Cohort 2:
N = 50,060

*See Methods for definitions. Abbreviations: AKI – acute kidney injury; CKD – chronic kidney disease; eGFR – estimated glomerular filtration rate; KTx – kidney transplant; HD – hemodialysis; PD – peritoneal dialysis; RRT – renal replacement therapy.
Supplementary Figure 2. Love plots summarising the effect of covariate balancing according to COVID-19 status (i.e. positive versus negative) (a) in patients with CKD (Panel A: Cohort 1; Panel C: Cohort 2) and in patients without CKD (Panel B: Cohort 1; Panel D: Cohort 2), and the effect of covariate balancing according to CKD status (i.e. CKD versus no CKD) (b) in patients with COVID-19 (Panel A: Cohort 1; Panel C: Cohort 2) and in patients without COVID-19 (Panel B: Cohort 1; Panel D: Cohort 2). Abbreviations: ACE-inhibitor – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; SIMD – Scottish index of multiple deprivation.

a) Covariate balancing according to COVID-19 status

A

B

C

D

ACE–inhibitor or ARB
Age (years)
Age (years) [squared]
Cancer
Chronic liver disease
Chronic lower respiratory disease
Diabetes mellitus
Heart failure
Immunosuppressants
Previous myocardial infarction
Previous stroke
Sex
SIMD 1
SIMD 2
SIMD 3
SIMD 4
SIMD 5
Stable angina

0.00 0.05 0.10 0.15

0.00 0.02 0.04 0.06 0.08

0.00 0.05 0.10 0.15

0.00 0.02 0.04 0.06

Absolute
Standardized
Mean
Differences
Kolmogorov–Smirnov
Statistics

Sample Unadjusted Adjusted

0.00 0.1 0.2

0.00 0.05 0.1 0.15

0.00 0.06

0.00 0.02 0.04

0.00 0.3 0.06

0.00 0.02 0.04

0.00 0.05 0.1 0.15

0.00 0.02 0.04 0.06

0.00 0.05 0.1 0.15

0.00 0.02 0.04 0.06

0.00 0.05 0.1 0.15

0.00 0.02 0.04 0.06
b) Covariate balancing according to CKD status
Supplementary Figure 3. Survival curves for cardiovascular (a) and all-cause death (b) according to CKD status (i.e. CKD versus no CKD) for patients with COVID-19 (Panel A: Cohort 1; Panel C: Cohort 2) and patients without COVID-19 (Panel B: Cohort 1; Panel D: Cohort 2). 

a) Cardiovascular death

A) COVID-19 positive – Cohort 1

B) COVID-19 negative – Cohort 1

C) COVID-19 positive – Cohort 2

D) COVID-19 negative – Cohort 2
b) All-cause death

A) COVID-19 positive – Cohort 1

B) COVID-19 negative – Cohort 1

C) COVID-19 positive – Cohort 2

D) COVID-19 negative – Cohort 2

CKD status
- No CKD
- CKD
**Supplementary Figure 4.** Forest plot summarising adjusted hazard ratios (HR) from Cohorts 1 and 2 and associated pooled meta-estimates for cardiovascular (a) and all-cause death (b) according to CKD status (i.e. CKD versus No CKD) for patients with COVID-19 (red) and for patients without COVID-19 (blue) at 30 days (top panel), 90 days (middle panel) and to the end of study follow-up (bottom panel).

### a) Cardiovascular death

|                | HR  | lower | upper |
|----------------|-----|-------|-------|
| **COVID positive – 30 days** |     |       |       |
| Cohort 1       | 1.71| 1.04  | 2.82  |
| Cohort 2       | 1.70| 1.14  | 2.54  |
| **Summary**    | 1.71| 1.25  | 2.33  |
| **COVID negative – 30 days** |     |       |       |
| Cohort 1       | 1.17| 0.92  | 1.48  |
| Cohort 2       | 1.58| 1.30  | 1.92  |
| **Summary**    | 1.40| 1.20  | 1.63  |
| **COVID positive – 90 days** |     |       |       |
| Cohort 1       | 1.90| 1.21  | 2.97  |
| Cohort 2       | 1.62| 1.12  | 2.33  |
| **Summary**    | 1.73| 1.30  | 2.29  |
| **COVID negative – 90 days** |     |       |       |
| Cohort 1       | 1.31| 1.08  | 1.58  |
| Cohort 2       | 1.66| 1.43  | 1.92  |
| **Summary**    | 1.52| 1.35  | 1.71  |
| **COVID positive – study end** |     |       |       |
| Cohort 1       | 1.69| 1.15  | 2.47  |
| Cohort 2       | 1.61| 1.17  | 2.21  |
| **Summary**    | 1.64| 1.29  | 2.10  |
| **COVID negative – study end** |     |       |       |
| Cohort 1       | 1.29| 1.10  | 1.50  |
| Cohort 2       | 1.56| 1.39  | 1.75  |
| **Summary**    | 1.46| 1.33  | 1.60  |

### b) All-cause death

|                | HR  | lower | upper |
|----------------|-----|-------|-------|
| **COVID positive – 30 days** |     |       |       |
| Cohort 1       | 1.25| 1.04  | 1.52  |
| Cohort 2       | 1.21| 1.02  | 1.43  |
| **Summary**    | 1.23| 1.08  | 1.39  |
| **COVID negative – 30 days** |     |       |       |
| Cohort 1       | 1.16| 1.01  | 1.34  |
| Cohort 2       | 1.31| 1.16  | 1.47  |
| **Summary**    | 1.25| 1.14  | 1.36  |
| **COVID positive – 90 days** |     |       |       |
| Cohort 1       | 1.27| 1.06  | 1.51  |
| Cohort 2       | 1.21| 1.04  | 1.42  |
| **Summary**    | 1.24| 1.10  | 1.39  |
| **COVID negative – 90 days** |     |       |       |
| Cohort 1       | 1.21| 1.09  | 1.34  |
| Cohort 2       | 1.32| 1.21  | 1.44  |
| **Summary**    | 1.27| 1.19  | 1.36  |
| **COVID positive – study end** |     |       |       |
| Cohort 1       | 1.27| 1.08  | 1.51  |
| Cohort 2       | 1.24| 1.07  | 1.43  |
| **Summary**    | 1.25| 1.12  | 1.41  |
| **COVID negative – study end** |     |       |       |
| Cohort 1       | 1.17| 1.08  | 1.27  |
| Cohort 2       | 1.31| 1.22  | 1.41  |
| **Summary**    | 1.24| 1.18  | 1.31  |
Supplementary Figure 5. Adjusted hazard ratios of cardiovascular (a) and all-cause death (b) according to eGFR (ml/min/1.73 m²), in patients with COVID-19 (Panel A: Cohort 1; Panel C: Cohort 2) and in patients without COVID-19 (Panel B: Cohort 1; Panel D: Cohort 2). 

a) Cardiovascular death
b) All-cause death

A COVID-19 positive – Cohort 1

B COVID-19 negative – Cohort 1

C COVID-19 positive – Cohort 2

D COVID-19 negative – Cohort 2
Supplementary Figure 6. Forest plot summarising adjusted hazard ratios (HR) from Cohorts 1 and 2 and associated pooled meta-estimates for COVID-19-related death according to CKD status (i.e. CKD versus no CKD) at 30 days (top panel), 90 days (middle panel) and to the end of study follow-up (bottom panel).

|               | HR   | lower | upper |
|---------------|------|-------|-------|
| **30 days**   |      |       |       |
| Cohort 1      | 1.32 | 1.09  | 1.61  |
| Cohort 2      | 1.20 | 1.01  | 1.42  |
| Summary       | 1.25 | 1.10  | 1.42  |
| **90 days**   |      |       |       |
| Cohort 1      | 1.35 | 1.12  | 1.63  |
| Cohort 2      | 1.20 | 1.02  | 1.41  |
| Summary       | 1.26 | 1.12  | 1.43  |
| **Study end** |      |       |       |
| Cohort 1      | 1.36 | 1.12  | 1.64  |
| Cohort 2      | 1.20 | 1.02  | 1.42  |
| Summary       | 1.27 | 1.12  | 1.43  |
**Supplementary Figure 7.** Adjusted hazard ratios of COVID-19-related death according to estimated glomerular filtration rate (ml/min/1.73 m²) in Cohort 1 (a) and Cohort 2 (b).

a) **Cohort 1**

![Graph of Adjusted Hazard Ratio vs. Estimated GFR for Cohort 1](image)

b) **Cohort 2**

![Graph of Adjusted Hazard Ratio vs. Estimated GFR for Cohort 2](image)
References

1. SMR Datasets - SMR Validation Section [Available from: https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets/SMR-Validation-Section/]
2. Assessment of SMR01 Data Scotland 2014-2015 [Available from: https://www.isdscotland.org/Products-and-Services/Data-Quality/docs/Assessment-of-SMR01-Data-2014-15-report-180508.pdf]
3. Shah ASV, McAllister DA, Gallacher P, Astengo F, Rodriguez Perez JA, Hall J, et al. Incidence, Microbiology, and Outcomes in Patients Hospitalized With Infective Endocarditis. Circulation. 2020;141(25):2067-77.
4. National Records of Scotland - Vital Events - Deaths [Available from: https://www.nrscotland.gov.uk/files/statistics/vital-events/ve-deaths-cause-of-death-text-codes.pdf]
5. Wild S, Fischbacher C, McKnight J. Using Large Diabetes Databases for Research. Journal of Diabetes Science and Technology. 2016;10(5):1073-8.
6. Government S. Scottish Index of Multiple Deprivation 2020 2020 [updated 28/01/2020. Available from: https://www.gov.scot/publications/scottish-index-of-multiple-deprivation-2020/pages/1/]
7. Scottish Index of Multiple Deprivation 2020 [Available from: https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/]
8. Norton JM, Ali K, Jurkovitz CT, Kiyrluk K, Park M, Kawamoto K, et al. Development and validation of a pragmatic electronic phenotype for CKD. Clinical Journal of the American Society of Nephrology. 2019;14(9):1306-14.
9. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009;150(9):604-12.
10. Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):5-14.
11. Scottish Care Information Diabetes Collaboration [Available from: https://www.sci-diabetes.scot.nhs.uk/]
12. Funk MJ, Westreich D, Wiesen C, Stürmer T, Brookhart MA, Davidian M. Doubly robust estimation of causal effects. American journal of epidemiology. 2011;173(7):761-7.
13. Li X, Shen C. Doubly robust estimation of causal effect: upping the odds of getting the right answers. Circulation: Cardiovascular Quality and Outcomes. 2020;13(1):e006065.
14. Imai K, Ratkovic M. Covariate balancing propensity score. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2014;76(1):243-63.
15. Williams B, Zhang Y. Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19. The Lancet. 2020;395(10238):1671-3.
16. Thng ZX, De Smet MD, Lee CS, Gupta V, Smith JR, McCluskey PJ, et al. COVID-19 and immunosuppression: a review of current clinical experiences and implications for ophthalmology patients taking immunosuppressive drugs. British Journal of Ophthalmology. 2021;105(3):306-10.
17. Royston P, Sauerbrei W. Multivariable modeling with cubic regression splines: a principled approach. The Stata Journal. 2007;7(1):45-70.
18. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. Available from: https://www.equator-network.org/reporting-guidelines/strobe/ . Accessed 11/02/2021. [cited 2021. Available from: https://www.equator-network.org/reporting-guidelines/strobe/.
Cardiovascular outcomes in patients with chronic kidney disease & COVID-19: a multi-regional data-linkage study

**Methods**

- SARS-CoV-2 PCR
- 86,964 patients with prior measures of serum creatinine tested in Scotland, UK

Cohort 1: N = 36,904
- CKD = 15.9%

Cohort 2: N = 50,060
- CKD = 16.4%

Primary outcomes:
- Cardiovascular death
- All-cause death

**Covariate Balancing Propensity Score**
- Weighted comparison by test status

**Results**

| CKD | SARS-CoV-2 (+): 11.4% |
|-----|----------------------|
| •   | Outcomes in patients with COVID-19: |
|     | - Cardiovascular death: 11.1% |
|     | - COVID-19 death: 36.8% |
|     | - All-cause death: 46.5% |

| No CKD | SARS-CoV-2 (+): 9.2% |
|--------|---------------------|
| •      | Outcomes in patients with COVID-19: |
|        | - Cardiovascular death: 2.7% |
|        | - COVID-19 death: 12.5% |
|        | - All-cause death: 16.3% |

**COVID-19 (+) vs (-) → EXCESS RISK in PATIENTS WITH CKD**

Adjusted meta-estimates combining both cohorts for cardiovascular and all-cause death

|  | Hazard ratio | Lower 95% CI | Upper 95% CI |
|  | 30 days | 2.34 | 1.83 | 2.99 |
|  | 90 days | 1.71 | 1.39 | 2.11 |
|  | Study end | 1.57 | 1.31 | 1.89 |

30 days: 4.53, 3.97, 5.16
90 days: 3.01, 2.68, 3.35
Study end: 2.41, 2.17, 2.64